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 STUDY OF TESTOSTERONE LEVELS IN MEN WITH TYPE 2 
DIABETES MELLITUS 
ABSRACT 
BACKGROUND 
 Diabetes Mellitus, one of the most common non- communicable diseases, is 
a chronic metabolic disorder which is heralded by a number of micro-vascular and 
macro-vascular complications which are well known of. But the other 
endocrinological perspective of diabetes is often not given much importance. Most 
diabetics are associated with low levels of testosterone. Yet this aspect is not often 
investigated mainly because hypotestosteronemia is usually attributed to the aging 
process rather than diabetes itself. Moreover the symptoms of hypotestosteronemia 
are mostly non-specific, further making the diagnosis more elusive. The purpose of 
our study is to bring forth this association between type 2 diabetes mellitus and 
hypotestosteronemia. 
METHODOLOGY 
We started the study with the selection of cases and controls. We selected 
100 diabetic men from our Diabetology OPD, Chengalpattu Medical College who 
fitted into the inclusion criteria as our cases. As controls, we selected subjects 
without history of diabetes mellitus whose FBS was less than 126 mg/dl on two 
occasions, from our male Medical OPD. Anthropometric measurements like 
height, weight, waist and hip circumferences were measured and BMI and Waist 
Hip ratio were calculated. Total cholesterol was measured. Total testosterone in the 
early morning (8:00–10:00 AM) was measured using CLIA (Chemiluminescence 
enzyme immunoassay)  method. The average serum testosterone levels were 
compared between the diabetic and non-diabetic men and was statistically 
analysed. The diabetic patients were further grouped, based on the duration of 
diabetes, BMI, cholesterol levels and presence or absence of associated risk factor 
and analysed. 
RESULT 
 It was observed that on comparing the average total testosterone level 
between the two groups, we found that, there was a significant decrease in the 
testosterone levels in the diabetics compared to that of the non-diabetics in each 
age group. We also found that as the age progress there is a steady decline in the 
serum levels of testosterone in both the groups. But the fall in the testosterone 
values is much more significant in the diabetics. 
Statistical analysis was made and the P values were calculated by the student 
T- test. The association between the diabetic and non-diabetics in each age group 
was found to be significant with a P-value of <0.05. Thus the decrease in the serum 
level of testosterone is found to be significant. 
As the second part of our study we compared the serum testosterone levels 
among the diabetic men, by separating them into smaller groups, using multiple 
parameters such as duration of diabetes, BMI, Waist Hip ratio, cholesterol levels, 
associated other risk factors. We were able to derive an inverse relation between 
serum testosterone levels and most of these parameters. Thus we also evaluated the 
effects of multiple risk factors on diabetic men and testosterone levels. 
CONCLUSION 
Thus, through this study we demonstrate the association between type 2 
diabetes mellitus and testosterone. We conclude that, there is a significant 
reduction in the levels of serum testosterone in diabetic men as compared to that of 
non-diabetic men. Even though the declining trend of the testosterone levels occurs 
as the age increases the reduction in the testosterone levels are more significant in 
the diabetic group as compared to that of the non-diabetic men. Thus from our 
study we propose that age factor alone is not the cause of hypotestosteronemia in 
diabetes men. 
 From the analyses of different factors like BMI, cholesterol and other risk 
factors we have shown the influence of multiple factors on the levels of 
testosterone. Thus, in diabetic patients, hypotestosteronemia is a common entity. 
We suggest the measurement of testosterone in patients with diabetes, as the 
replacement of testosterone can have multiple benefits in diabetic patient to 
prevent diabetic complication and cardiovascular diseases. Testosterone level can 
further predict the development of type 2 diabetes mellitus, the utilization of this 
aspect of testosterone in future, is not too far. 
KEY WORDS 
Type 2 diabetes mellitus, testosterone, and risk factors, BMI 
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INTRODUCTION 
 
 
Testosterone a 19-carbon steroid secreted by the testis (Leydig cells) is the 
primary circulating androgen in the male human. Testosterone is essential for 
health and well-being and its levels decreases with aging. Men with type 2 
diabetes mellitus have low testosterone levels, but this concept has not received 
much attention because of the fact that both type 2 diabetes and 
hypotestosteronemia are associated with aging. But studies have shown that 
young men with type 2 diabetes mellitus do suffer from low testosterone levels. 
Testosterone plays a vital role in the metabolism of glucose and lipid. 
Decreased levels of serum testosterone often have adverse effects on the 
metabolic profile.  Epidemiological studies have shown that there is a direct 
relationship between the serum testosterone levels and insulin sensitivity, and 
that hypotestosteronemia is associated with an increased risk of type 2 diabetes 
mellitus. It is also found that there is an inverse correlation between serum 
testosterone and fasting insulin levels in men irrespective of age and obesity. 
The mitochondrial dysfunction is the key factor leading to insulin resistance in 
men. 
Lower total testosterone and sex hormone-binding globulin (SHBG) 
predict a higher incidence of metabolic syndrome. There is evidence that 
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hypotestosteronemia should be an element in the definition of metabolic 
syndrome, since low levels of testosterone are associated with or predict the 
development of metabolic syndrome and of diabetes mellitus. 
   In men with decreased serum levels of testosterone and type 2 diabetes 
mellitus, C-reactive protein concentration have found to be decreased which 
leads to increased risk of developing atherosclerosis and coronary heart disease 
independent of the risk associated with diabetes mellitus alone. 
Further testosterone replacement suggests that there is a shift of fat mass to 
lean body mass. Both the systolic and diastolic blood pressure reduced and the 
mean plasma glucose levels declined. There was a significant improvement in 
lipid profiles. There was also an initial significant decrease in levels of liver 
enzymes. Additionally, there was a marked reduction in the C-reactive protein 
levels. 
 Further perspective is the healing of the diabetic ulcers with testosterone 
replacement therapy and therefore the use of testosterone in recalcitrant ulcers. 
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AIMS & OBJECTIVES 
 
 To evaluate the level of serum testosterone in men with type 2 
Diabetes Mellitus and to compare it with that of non-diabetic men 
of the same age. 
  Effect of multiple parameters like obesity, hypertension etc. on 
the serum testosterone levels in men with type 2 Diabetes 
Mellitus. 
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REVIEW OF LITERATURE 
 
Though the effects of testosterone have been known since ancient times, 
it was Ernest Laqueur [1] who first used the term testosterone (T) in 1935 when 
he isolated it from the bull testes. It is derived from the German word  
Testosteron (1935), coined from a presumed combined form of L. testis 
"testicle" (testis) + ster(ol) (steroid) + chemical ending -one.[2]  
 
HISTORICAL MILESTONES: 
The researches done on testosterone dates back to the 1800 [3].  Since 
antiquity, medicine men and scientists had the knowledge that castration of the 
testes leads to the loss of the vitality of men and animals. A German 
physiologist, Arnold Berthold [4], in 1849 experimented with four roosters, 
where he removed the testes in two roosters and transplanted it into the 
abdominal cavity of the other two [5]. The castrated roosters became fat and lazy 
which is a sign of testosterone loss.  The two with grafted testes remained a 
rooster with bright red combs. [6] 
Ernest Laqueur received the Nobel Prize [7] in 1935 for isolating the 
testosterone molecule. It was found in 1951 that, testosterone will produce a 
positive nitrogen balance and can increase the lean muscle mass [8].  This forms 
the basis that testosterone can be useful in the treatment of cardiovascular 
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disease [9] by synthesis of protein. With positive nitrogen balance there is 
increased protein synthesis which leads to easy repair of the bodily structures 
when damaged [10]. In addition, testosterone also induces the production and 
synthesis of the protein enzymes which are useful for the structure and 
functioning of the organs.  
It was in 1935 that the newer era of modern testosterone therapy began, 
when Aldolf Butenandt [11] and Leopold Ruzicka [12] synthesized testosterone 
chemically. Oral forms of testosterone were found ineffective and 17-alkylated 
derivatives of testosterone which was used orally became obsolete later due to 
its side effects. So other methods of testosterone delivery were tried. A buccal 
testosterone tablet [13] was introduced which adheres to the buccal mucosa and 
by dissolving slowly released testosterone. Implants of crystalline testosterone 
were also inserted in the subcutaneous tissue. The other form was as 
testosterone gels which were opted for its ease in application. During 1950 and 
60’s researches intensified to aid modifications in the testosterone preparations 
[14]. Orally effective T undecanoate was introduced during 1970’s. Transdermal 
scrotal patches [15, 16] were invented in 1992. Non-scrotal transdermal patches [17] 
were accessible then in 2000. The most recent preparations used in testosterone 
replacement therapy are the injectable forms which includes testosterone 
enanthate, cypionate, and undecanoate [18].  
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Though we are very much aware of the association of type 1 diabetes 
mellitus with that of other endocrine disorders [19], that is the Polyglandular 
Autoimmune (PGA) Syndromes which includes adrenal insufficiency, type 1 
diabetes mellitus, autoimmune thyroid disease, hypophysitis, celiac disease, 
atrophic gastritis, pernicious anemia, vitiligo, hypoparathyroidism, myasthenia 
and thymoma, the association of type 2 diabetes with other endocrinological 
abnormalities is not well established. Around early nineties studies involving 
the association between type 2 diabetes mellitus and hypotestosteronemia 
began. 
Since 1960 researches were conducted on the role of testosterone on the 
cardiac well-being, its association with other cardiovascular risk factors and 
metabolic syndrome [20, 21]. The knowledge of low levels of serum testosterone 
as a reason for the all-cause mortality has led way to further researches. By 
many studies it is now proved that apart from attenuation of sexual symptoms 
testosterone supplementation also has other beneficial effect [22, 23]. 
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 BACKGROUND: 
Over the last few years, there have been several reports demonstrating 
that men with type 2 diabetes mellitus (T2DM) have a higher prevalence of 
hypotestosteronemia compared to that of normal population [24]. It has been 
found that reduced testosterone level is associated with increased risk of 
metabolic syndrome and diabetes [25].  In men, hypotestosteronemia has been 
observed to be associated with obesity, upper body fat distribution, and 
increased level of glucose and insulin [26]. Men with low serum testosterone 
levels present with loss of sexual interest, decreased vigor, depression, reduced 
bone strength, redistribution of body fat, easy fatigability. As these symptoms 
are usually non- specific, hypotestosteronemia is frequently under diagnosed 
[27]. Compared to normal population, individuals with hypertension, obesity, 
hyperlipidemia and diabetes have hypotestosteronemia [28, 29]. The purpose of 
this study, therefore, is to evaluate the serum level of testosterone in males with 
type 2 diabetes. 
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TESTOSTERONE:  
Secretion: 
The male gonad, testes secretes the male sex hormones, which are known 
as the androgens [30]. This includes testosterone, dihydrotestosterone, and 
androstenedione. Among these three hormones, testosterone is found to be 
secreted in larger quantities and so it is considered to be the important testicular 
hormone. It is to be noted that the testosterone eventually gets converted to 
dihydrotestosterone which then acts on the target tissues.  
 
 
 
The Interstitial cells of Leydig [31], which are polyhedral cells that lies as 
clusters between the seminiferous tubules elaborates the hormone testosterone, 
and it is the main source of the hormone. The Leydig cells number and activity 
16
parallel that of the testosterone surge. They are found to be more numerous in 
neonates in the initial months and then in the post pubertal adulthood period. In 
the childhood period these Leydig cell are scanty and so there is no detectable 
testosterone [32]. 
 
Chemistry [33]:  
Testosterone, the principal testicular hormone is a steroidal compound, a 
C19 steroid with an -OH group in the 17 position. Its molecular formula being, 
C19H28O2. 
 
 
 
Synthesis: 
Testosterone is derived [34] from cholesterol, the major site of synthesis 
being the Leydig cells of the testes. Adrenal cortex also shares its contribution 
by the secretion of androstenedione which then gets further converted into 
testosterone. The rate limiting step in testicular steroidogenesis is the entry of 
17
cholesterol into the mitochondria which need a transport protein. The initial step 
begins with the conversion of cholesterol to pregnenolone when it is acted upon 
by the side chain cleavage system. [35]. Pregnenolone is further converted into 
testosterone by two pathways, either by the progesterone pathway or by the 
dehydroepiandrosterone pathway. The array of enzymes which are involved 
includes 3 beta hydroxysteroid dehydrogenase, 17 alpha hydroxylase and 17, 20 
lyase, 17 beta hydroxysteroid dehydrogenase. Reduction of the adrostenedione 
at the 17th carbon position results in the formation of testosterone. 
 
 
Transport and Metabolism:  
Testicular secretion of testosterone contributes to the major quantity of 
the testosterone in the circulation. It constitutes around 90-95%. The rest is 
contributed by the adrenal steroidogenesis and from the conversion of 
androstenedione to testosterone in the periphery [36]. The most important 
metabolic product of testosterone is dihydrotestosterone. It is mainly produced 
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peripherally from testosterone by a reaction that is catalyzed by the enzyme 5 
alpha reductase, although the testes secrete a very minor quantity of 
dihydrotestosterone. In many tissues like the external genitalia, prostrate and 
some parts of the skin, dihydrotestosterone is the active form of the hormone. 
The production of dihydrotestosterone is around 400 micro grams as compared 
to about 5 grams of testosterone which shows that the plasma concentration of 
dihydrotestosterone is only one-tenth of that of testosterone concentration in 
adult males. 
Testosterone gets metabolized by two pathways. The first pathway which 
involves oxidation is the major pathway. It occurs in many tissues including the 
liver and the end product being ketosteroids which are usually less active than 
testosterone. The second pathway involves reduction of the double bond and it 
occurs in the target tissues. The end product is dihydrotestosterone which is 
more potent than testosterone. 
In male a small quantity of testosterone is converted into estradiol by 
peripheral aromatization and this contributes to about 80% of the circulating 
estradiol in men. 
98% of the testosterone in the circulation is bound to protein the rest 
remains unbound as free hormone and it is this unbound free form which is 
biologically active. About 65% is bound to beta globulin also called the sex 
hormone–binding globulin SHBG [37] which has more affinity towards 
testosterone. The changes in the concentration of SHBG reflect upon in the 
19 
 
plasma level of testosterone. Conditions producing a decrease in SHBG are 
obesity, diabetes, administration of androgens, while aging and estrogen 
produces an increase. About 33% of the testosterone is bound to albumin. 
The plasma testosterone level (free and bound) is 300-1000ng/dl in adult 
men and 30-70ng/dl in adult women. 
 
Control of Testicular functions: 
 The secretion of testosterone is under the influence of the Luteinizing 
hormone (LH) secreted by the anterior pituitary. LH acts on the Leydig cells [38] 
and stimulates them to secrete testosterone. Excess testosterone in turn 
suppresses the secretion of LH from the pituitary. Testosterone does not have 
much influence on FSH (Follicle stimulating hormone) whereas another 
hormone called inhibin which is secreted by the Sertoli cells decreases the FSH 
concentration.  
 
Steroid Feedback:  
        The current "working hypothesis" of the way the functions of the testes are 
regulated involves the feedback control of the LH on the Leydig cells and by 
FSH on the Sertoli cells. These in turn by the secretion of testosterone and 
inhibin controls the secretion of LH and FSH respectively. These feedback 
mechanisms are further under the control of GnRH secretion from the 
hypothalamus. It is to be noted that testosterone also has inhibitory control over 
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GnRH apart from LH. Castration is followed by a rise in the pituitary content 
and secretion of FSH and LH [39], and hypothalamic lesions prevent this rise. [40, 
41]. Disorders involving the hypothalamus can lead to atrophy of the testes. 
 This hypothesis can be used upon clinically. Systemically administered 
testosterone has not found to increase the concentration of androgen in the 
local environment of the testes (a phenomenon which is necessary for normal 
spermatogenesis to occur i.e. increased concentration of androgens around the 
Sertoli cells) and this causes inhibition of LH secretion. Thus the ultimate 
effect of administering testosterone systemically is to produce a decreased 
sperm count. Thus is the use of testosterone as a method of contraception [42]. 
The main drawback is the need to use testosterone at very high doses, at with it 
produces side effects like sodium and water retention. 
21
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Mechanism of Androgen Action [43]: 
The androgen receptor (AR) [44] belongs to the superfamily of receptors 
which have highly conserved DNA binding domain in common-the nuclear 
receptor super family. The long arm of the X chromosome [45] codes for the 
androgen receptors.  
 Testosterone binds itself to an intracellular receptor and forms a receptor-
steroid complex. This complex then binds to the DNA in the nucleus leading to 
transcription of various genes [46, 47]. Other mechanism of androgen action is 
through non-genomic mechanism. 
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Basic Intracellular Mechanism of Action of Testosterone 
Most of the effects of testosterone result basically from an increased rate 
of protein formation in the target cells. This has been studied extensively in the 
prostate gland, one of the organs that is most affected by testosterone. In this 
gland, testosterone enters the prostatic cells within a few minutes after 
secretion. Then it is most often converted, under the influence of the 
intracellular enzyme 5 alpha-reductase [48], to dihydrotestosterone, and this in 
turn binds with a cytoplasmic “receptor protein” [49]. This combination migrates 
to the cell nucleus, where it binds with a nuclear protein and induces DNA-
RNA transcription. Once the RNAP gets activated, the amounts of the RNA 
starts to rise, which then leads to a significant raise in the protein content of the 
cells [50]. After several days, the quantity of DNA in the prostate gland also 
increases and there is a simultaneous increase in the number of prostatic cells. 
Testosterone stimulates production of proteins virtually everywhere in the body, 
although more specifically affecting those proteins in “target” organs or tissues. 
Thus testosterone leads to the development of the primary sexual characteristics 
and those of secondary too. Recent studies suggest that testosterone, like other 
steroidal hormones, may also exert some rapid, non-genomic effects that do not 
require synthesis of new proteins. The physiological role of these non-genomic 
actions of testosterone, however, has yet to be determined. 
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Functions of Testosterone 
 
In general, testosterone is responsible for the development of male body 
configuration. Even during fetal life, the testes are stimulated by chorionic 
gonadotropin from placenta to produce moderate quantities of testosterone 
throughout the entire period of fetal development and for 10 or more weeks 
after birth; thereafter, essentially no testosterone is produced during childhood 
until about the ages of 10 to 13 years. Under the influence of the luteinizing 
hormone from the anterior pituitary, the Leydig cells begin to secrete 
testosterone. This increase in testosterone starts with the beginning of puberty 
and continues secretion thereafter. As the age increases, the amount of 
testosterone secretion decreases, declining progressively after the age of 50yrs 
with the maximum fall being after the age of 80 yrs.  
 
Functions of Testosterone during Fetal Development: 
 
Testosterone begins to be elaborated by the male fetal testes at around 
seventh week of intra uterine life [51]. It can be said that, the main impetus for 
the development of a male fetus is the secretion of testosterone by the fetal 
gonads, which is mediated by the presence of the Y-chromosome. Testosterone 
also mediates the development of male internal genitalia and 
dihydrotestosterone (its active metabolite) mediates the development of the 
external genitalia. Those in which these impetuses are absent will develop into a 
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female fetus.  By experimental studies it has been proved that when a large 
amount of testosterone is injected into a pregnant animal, even if the fetus was a 
female, it led to the development of male sex organs [52]. It was also found that 
when the testes were castrated early from a male fetus it developed female sex 
organs. These prove the essentiality of testosterone for the development of both 
the internal and the external genitalia in a male fetus [53] and at the same time it 
inhibits the development of female sex organs.  
 
Effect of Testosterone to Cause Descent of the Testes. The testes usually 
descend into the scrotum during the 8th to 9th month [54] of gestation during 
which the testes begin secreting reasonable quantities of testosterone. If a male 
child is born with undescended but otherwise normal testes, injection of 
testosterone has been found to causes the descent of the testes normally. 
Administration of gonadotropic hormones also, which stimulate the Leydig cells 
of the newborn child’s testes to produce testosterone, can also cause the testes to 
descend. Thus, the stimulus for descent of the testes is testosterone [55], 
indicating that testosterone is an important hormone for male sexual 
development during fetal life. 
 
 
Functions of Testosterone after puberty: 
 
Effect of Testosterone on Development of Adult Primary and Secondary 
Sexual Characteristics: 
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After puberty, the so long quiescent testes begin to secrete testosterone and 
the testosterone concentration increases considerably.  This leads to certain 
changes in the external genitalia of the male i.e. enlargement of these organs. 
There is also enlargement of the prostate gland and the seminal vesicles with 
production of fructose by the seminal vesicles. The second important function 
of testosterone during puberty is the emergence of secondary sexual 
characteristics. These two are the very essential characters because it helps in 
distinguishing a man physically. Testosterone also enhances the male psychic 
effects. 
 
Effect on the Distribution of Body Hair:  
Testosterone causes the male pattern of hair growth over the body. These 
usually are present: 
(1) On the beard area with the development of moustache 
  (2) Over the chest  
(3) Over the abdomen along the linea alba up to the pubic symphysis  
(4) Also on the back along the shoulders  
(5) Pubic hair growth. It can also produce hair growth anywhere in the 
body but it generally decreases the scalp hair growth. 
 
Baldness: As mentioned above, testosterone reduces the scalp hair growth 
especially on the crown of the head [56]; experimental studies have proved that 
castration of testes never produces baldness. But testosterone alone is not the 
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sole reason for baldness; it is the interplay of many factors especially genetic 
factors [57] followed by excessive androgens [58].  
 
Effect on the Voice: 
The masculine type of voice is a harsh and low pitched voice. This 
character to the voice is produced by testosterone. Testosterone makes the 
laryngeal mucosal hypertrophy with resultant laryngeal enlargement. Around 
puberty the voice become discordant initially which is termed “cracking” voice 
[59], this is followed by a gradual change to voice of an adult male. 
 
Testosterone Increases Thickness of the Skin and contribute to 
Development of Acne:  
Testosterone produces certain structural changes in the skin. Firstly it 
increases the skin thickness of the whole body and produces ruggedness of the 
tissues. Secondly it acts on the sebaceous glands and causes its growth and 
increases the secretion of sebum from the sebaceous glands. This results in the 
production of acne especially over the face [60]. Therefore, acne is a common 
feature of male adolescence when the body is first becoming introduced to 
increased testosterone. After several years of testosterone secretion, the skin 
normally adapts to it in a way that allows it to overcome the acne. 
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Testosterone Increases Protein Formation and Muscle Development [61]: 
One of the most important male characteristics is the development of 
increasing musculature after puberty, averaging about a 50 per cent increase in 
muscle mass over that in the female. This is associated with increased protein 
formation in the non-muscular parts of the body as well. Many of the changes in 
the skin are due to deposition of proteins in the skin, and changes in the voice 
also result partly from this protein anabolic function of testosterone. Because of 
this great effect that testosterone and other androgens have on the body 
musculature, synthetic androgens are widely used by athletes to improve their 
muscular performance. This practice is to be severely deprecated because of the 
fact that prolonged harmful effects of excess androgens, in relation to sports 
physiology. Testosterone or synthetic androgens are also occasionally used in 
elderly age as a “youth hormone” to improve muscle strength and vigor, but 
with questionable results. 
 
Testosterone Increases Bone Matrix and Causes Calcium Retention: 
After the great increase in circulating testosterone which occurs during 
puberty (or after prolonged injection of testosterone), the bones grow 
considerably thicker [62] and deposit considerable additional calcium salts. Thus, 
testosterone increases the total amount of bone matrix [63] and causes calcium 
retention. The increase in bone matrix is believed to be a result of the general 
protein anabolic function of testosterone plus deposition of calcium salts in 
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response to the increased protein. Testosterone gives the male pelvis a 
differentiating effect from that of the female pelvis thereby making it strong to 
bear heavy weights. In the absence of testosterone, the male pelvis develops into 
a pelvis that is similar to that of the female. Because of the ability of 
testosterone to increase the size and strength of bones, as aging occurs it can 
lead to decreased BMD and it is often used in older men to treat osteoporosis 
[64]. When greater amounts of testosterone (or any other androgen) are secreted 
abnormally in the still-growing child, the rate of bone growth increases 
markedly, causing a spurt in total body height. However, the testosterone causes 
the epiphyses of the long bones to unite with the shafts of the bones at an early 
age. Therefore, despite the rapidity of growth, this early uniting of the epiphyses 
prevents the person from growing as tall. Even in normal men, the final adult 
height is slightly less than that which occurs in males are castrated before 
puberty. 
 
Testosterone Increases Basal Metabolism [65]:  
Injection of large quantities of testosterone increases the basal metabolic 
rate by as much as 15 per cent. This increased rate of metabolism is possibly an 
indirect result of the effect of testosterone on protein anabolism, the increased 
quantity of proteins—the enzymes especially—increasing the activities of 
almost all the cells. 
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Effect on Red Blood Cells: 
When normal quantities of testosterone, is injected into a castrated adult, 
the number of red blood cells per cubic millimeter of blood increases by about 
15 to 20 per cent  [66]. Also, an average man has about 700,000 more red blood 
cells per cubic millimeter than an average woman. This difference is partly due 
to the increased metabolic rate that occurs after testosterone administration 
rather than to a direct effect of testosterone on red blood cell production. 
 
Effect on Electrolyte and Water Balance: 
Testosterone causes an increase in the distal tubular sodium reabsorption 
by the kidneys. Testosterone also has such an effect, but only to a minor degree 
when compared to that of the adrenal mineralocorticoids. Nevertheless, after 
puberty, the blood and extracellular fluid volumes of the males in relation to 
body weight increase as much as 5 to 10 per cent. 
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Normal Testosterone Levels in Men [67] by Age (Healthy) 
Measurements in SI Units (nmol/L)
Age TotalTest 
Free
Test SHBG 
25-34 21.38 0.428 35.5 
35-44 23.14 0.356 40.1 
45-54 21.02 0.314 44.6 
55-64 19.49 0.288 45.5 
65-74 18.15 0.239 48.7 
75-84 16.32 0.207 51.0 
85-100 13.05 0.186 65.9 
 
Measurements in Conventional Units ( ng/dl), SHBG in (nmol/L) 
Age TotalTest 
Free
Test SHBG 
25-34 617 12.3 35.5 
35-44 668 10.3 40.1 
45-54 606 9.1 44.6 
55-64 562 8.3 45.5 
65-74 524 6.9 48.7 
75-84 471 6.0 51.0 
85-100 376 5.4 65.9 
 
The normal testosterone level in young healthy males is between 300 and 
1000ng/dl. Testosterone level shows diurnal variations with lower value in the 
afternoon.  
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CAUSES OF HYPOTESTOSTERONEMIA [68] 
The causes of hypotestosteronemia are many to be enumerated. In a nutshell, 
there are three main levels at which defect can occur, finally leading to 
hypogonadism: 
1. The level of the hypothalamus  
2. The level of pituitary gland 
3. The level of the testes.  
When the defect lies in the hypothalamus or in the pituitary they are not 
able to produce appropriate quantities of gonadotrophins to stimulate 
adequate testicular secretions. Hence it is called hypogonadotrophic 
hypogonadism.  When the testes are at defect though there are adequate 
quantities of gonadotrophins the testes is not able to secrete adequate 
amounts of testosterone. Hence it is called hypergonadotropic 
hypogonadism.  In addition, SHBG also affects the serum testosterone 
levels. 
 When the defect involve the gonads, the testes, then it is termed as  
"primary hypogonadism  or primary gonadal failure[69] "   
 When the pituitary gland or its control over testosterone regulation  is at 
fault, it is termed as "secondary hypogonadism [69]," and  
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 When the defect lies high up in the hypothalamus, it is termed as 
"tertiary hypogonadism [69]." The last two entities are together called as 
hypogonadotrophic hypogonadism. 
 
PRIMARY HYPOGONADISM OR PRIMARY GONADAL FAILURE 
(TESTES): 
A. Primary gonadal failure may lead to defect in spermatogenesis, 
production and secretion of testosterone. 
B. Chromosomal abnormalities: Klinefelter's syndrome [70], in which there is 
an abnormal testicular development with reduced size of the testicles ad 
decreased production of testosterone. 
C. Anorchia syndrome [71] 
D. Uncorrected cryptorchidism [72] 
E. Acquired defects of the testes: 
1) Trauma to the scrotum resulting in testicular injury 
2) Torsion of testes leading to vascular insufficiency[73] 
3) Infections causing testicular damage (infectious orchitis): 
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 Viral orchitis may be caused by the mumps virus, group 
B arbovirus echovirus, lymphocytic choriomeningitis 
virus, most important of which is the mumps infection [74] 
 Other bacterial and parasitic infections. 
4) HIV infection[74] 
5) Tuberculosis and Lepromatous leprosy 
6) Toxic causes [75] 
 Drugs: ketoconazole (inhibition of testosterone 
synthesis), spironolactone (blockade of androgen action), 
marijuana and digitalis (increased estrogen)  
 Chemotherapeutic agent:  causes direct inhibition of 
Cyclophosphamide,procarbazine and patients on MOPP 
(mechlorethamine, oncovin, procarbazine, prednisone 
 Alcohol, when consumed in excess for prolonged 
periods, decreases testosterone, independent of liver 
disease or malnutrition.  
 Known environmental hazards include microwaves and 
ultrasound and chemicals such as nematocide 
dibromochloropropane, cadmium, phthalates, and lead. 
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7) Systemic illness: cirrhosis, chronic renal failure, sickle cell anemia,  
acute febrile illness, celiac disease  
8) Neurologic disorders: myotonic dystrophy [76], spinobulbar muscular 
atrophy, and paraplegia 
9) Androgen Insensitivity Syndromes 
10) Aging [77]: serum levels of testosterone declines with aging. But the 
available testosterone is still enough to carry out essential functions of 
the body. 
11) Hypotestosteronemia in women: Certain conditions in women cause 
low levels of serum testosterone. These includes bilateral 
oophorectomy due to any gynecological cause and premature ovarian 
failure  
 
SECONDARY  AND  TERTIARY  HYPOGONADISM : 
These are due to defect either at the level of the hypothalamus or the pituitary 
gland resulting in decreased production of the gonadotrophins (LH/ FSH/ 
GnRH) and failure of gonadal stimulation.  
 Some of the causes of hypogonadotrophic hypogonadism are: 
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1. Congenital Hypogonadotropic Disorders: 
Kallman's syndrome [78], Laurence-Moon syndrome, adrenal hypoplasia 
congenital, Prader-Willi syndrome. 
2. Acquired Hypogonadotropic Disorders 
 Tumors of the pituitary gland [79] 
 Brain tumors 
 Sellar Mass Lesions 
 Tuberculosis 
 Infiltrative diseases like hemochromatosis [80] sarcoidosis and 
histiocytosis X damages the pituitary gland  
 HIV and AIDS [74] affects the hypothalamus and pituitary 
 Anabolic steroid use 
 Obesity [81] 
 Hyperprolactinemia [83] 
 Severe Illness 
  Stress, Malnutrition 
  Exercise 
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Normally, the conversion of testosterone to estrogen [82] occurs in the 
adipocytes. In the presence of obesity, the amount of fat tissue mass that can act 
as a site for this conversion increases and hence there is more aromatisation 
reaction taking place thereby, decreasing the serum level of testosterone, due to 
its excessive conversion in to estrogen in the adipocytes. 
HYPOTESTOSTERONEMIA 
DEFINITION [84]: 
The American Association of Clinical Endocrinologists through detailed 
studies have come forward with the definition for hypogonadism which is 
defined as a serum level of testosterone <300ng/dl. [85, 86]. There is a diurnal 
variation in the level of testosterone. So it is better to measure the testosterone 
level in the morning rather than other timings i.e. around 8 a.m. in the morning  
[87, 88] In case the total testosterone levels are found to be subnormal before 
reporting it is always necessary to confirm it by a second test. Clinically there 
are certain indicators for the diagnosis of hypotestostreronemia, but most of 
these symptoms are non-specific. Hypotestostreronemia [89] is characterized by 
reduced sexual drive, reduced frequency of sexual intercourse or difficulty in 
maintaining erections, reduced growth of beard, loss of muscle mass, increased 
fat mass, decreased density of bone, decrease in testicular size, and enlargement 
of breast tissue. But only less than 10% of patients with erectile dysfunction 
alone have testosterone deficiency. Thus, it is always necessary to consider as a 
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whole, the entire symptomatology, to conclude as hypogonadism. Another 
lacuna in this area is that unless the symptoms are very profound it almost 
overlaps with the changes that occur in normal aging process.  
 
TESTOSTERONE ASSAY: 
When the word Total Testosterone (TT) is used, it means the measurement 
of both the bound form of testosterone as well as the unbound, free form. This 
total testosterone can be measured by a number of methods. Some of them are 
the radio-immuno assay method, liquid chromatography tandem mass 
spectrometry (LC-MS/MS) [90]. The more accurate method is the LC-MS/MS. 
This method is done by using organic solvents for the purpose of extracting the 
serum, followed by the isolation of testosterone from that of other steroids by 
the method of high-performance liquid chromatography and mass spectrometry, 
and finally to quantify the unique testosterone segments by mass spectrometry. 
The advantage of using this LC-MS/MS is that it is an accurate and a sensitive 
method for measuring even lower ranges of serum levels of testosterone. In 
future it is the method of choice for the estimation of serum levels of 
testosterone. Unlike many other hormone analyses, evaluation of testosterone 
levels can be accurate with the average testosterone levels with even a single 
sample but it must always be kept in mind that serum levels of testosterone 
fluctuate according to the pulsatile LH. When a patient presents with symptoms 
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consistent with hypogonadism, the initial step is the measurement of total 
testosterone in the morning sample using assay such as LC-MS/MS. 
Measurement of Unbound Testosterone Levels [91, 92] 
It is known that 98% of the plasma testosterone is bound to plasma 
proteins, either to sex hormone binding globulin (which carries most of the 
testosterone) or to albumin. The rest of the testosterone is called the unbound 
fraction or the free form. It should be noted that this form is the active form. 
This free form can be either calculated from the total testosterone levels and the 
sex hormone binding globulin by a formula called free androgen index in which 
ratio of total testosterone and the sex hormone binding globulin is obtained and 
expressed as percentage. Another method used for measurement of free 
testosterone is equilibrium dialysis method. Other method includes tracer 
analogue methods and though the results by this method are inaccurate it’s a 
more convenient method. Bioavailable testosterone is the term used to indicate 
the unbound free testosterone plus testosterone which is bound loosely to the 
albumin; this bioavailable testosterone is measured by the ammonium sulfate 
precipitation method. In elderly male and in patients in whom conditions 
associated with SHBG alterations are suggested, utilizing the equilibrium 
method for the direct measurement of free testosterone can be useful in 
unmasking testosterone deficiency 
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HCG Stimulation Test 
There are two methods to perform an hCG stimulation test.  [93] It can be 
performed either by administrating hCG as a single dose or as multiple doses 
and then recording the levels of testosterone. In the first method 1500–4000 IU 
of hCG is administered intramuscularly single dose. This is followed by 
measuring the level of serum testosterone at the baseline and then on 24, 48, 72, 
and 120 hours after injecting hCG. The second method is that of giving 1500 
units of hCG on three successive days amounting to three hCG doses. Serum 
testosterone levels are analyzed at least 24 hours since the last dose. The 
expected response to this hCG stimulation test is that, in an adult male, there 
should be a doubling of the testosterone concentration. This test is of main 
purpose in children, especially prepubertal aged. A response of testosterone 
levels to >150 ng/dL in a prepubertal child shows that testicular tissue is 
present. When there is no response to this test, it shows that either the testicular 
tissue is absent or there is a functional defect in Leydig cells. Another test 
which is useful in the evaluation of undescended testes is the measurement of a 
substance called MIS, Mullerian inhibiting substance, secreted by the Sertoli 
cells in prepubertal boys [94]. 
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LOW TESTOSTERONE IN TYPE 2 DIABETES 
Men suffering from type 2 diabetes mellitus are found to have a low serum 
testosterone levels on comparison with men who do not have a previous history 
of diabetes mellitus. It has also been found that there exists an inverse 
relationship between serum testosterone and HbA1c concentrations [95]. A 
number of Meta-analytic studies have shown that there is a profound 
hypotestosteronemia in men with type 2 diabetes mellitus [96]. Conversely in 
men suffering from hypotestosteronemia the risk of developing type 2 diabetes 
mellitus is high. About 30-50% of the diabetic men have found to have 
associated hypotestosteronemia. Recent researches prove that testosterone 
replacement therapy has been found to be beneficial in men with low 
testosterone levels with associated type 2 diabetes mellitus or metabolic 
syndrome [97]. 
Experimental studies showed that testosterone has found to afford 
protection to the endothelium of the blood vessels thereby maintaining the 
integrity of the vasculature. Thus hypotestosteronemia leads to endothelial 
dysfunctions and its sequelae, irrespective of the presence of any other risk [98]. 
Further lower serum levels of testosterone concentrations can cause stiffness of 
the arteries in men suffering from type 2 diabetes mellitus [99]. This appears to 
be one of the main contributing factors for the development of cardiovascular 
risks in diabetic men. 
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In men with type 2 diabetes mellitus presence of hypotestosteronemia is 
common entity but it still remains a hidden epidemic. This is in turn associated 
with insulin resistance. As the symptoms of hypogonadism are almost always 
nonspecific, it goes unnoticed unless profound. Some of the symptoms in 
diabetic men pointing towards testosterone deficiency include decreased libido, 
impaired mood, and low performance scale [100]. There appears to be a direct 
association   between hypotestosteronemia and development of cardiovascular 
risk factors. Furthermore there are evidences suggestive of an inverse 
relationship between hypotestosteronemia and insulin resistance, which in turn 
is strongly associated with the development of complications of diabetes 
mellitus both micro vascular and macro vascular[101]. Prospective studies have 
proved that in patients with decreased levels of total testosterone (TT) who have 
associated insulin resistance there is a higher risk for the development of type 2 
diabetes mellitus in future [102]. This is further proved by the fact that 
testosterone administration shows improvement in insulin sensitivity. 
As it was explained previously, SHBG is the major transporter protein of 
testosterone in the circulation. Another important fact which must be kept in 
mind is that a low serum concentration of SHBG can by itself be associated 
with the risk of developing type 2 diabetes mellitus irrespective of whether 
serum testosterone concentration is decreased or within the normal ranges. [103] 
SHBG are found to be reduced in a number of critical illnesses in which 
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conditions it acts as a confounding factor. Estimation of the free testosterone 
values rather than the total testosterone would useful under such conditions [104]. 
The prevalence of hypogonadism is much more common than expected in 
patients with type 2 diabetes mellitus. This association is proved to be present 
independent of certain important factors such as the duration of diabetes, the 
status of the glycemic control, presence of micro or macro vascular 
complications and whether associated  with other risk factor or not. Either alone 
or as a part of metabolic syndrome diabetes mellitus has a definitive association 
with diabetes mellitus.  
Another important aspect in the evaluation of hypogonadism is aging. 
Testosterone concentration steadily declines after the age of 50 yrs. The total 
testosterone levels fall around 0.5 to 2% each year to reach a maximum fall 
around 80yrs. In diabetic patients there is a more profound decline in the 
testosterone concentration adjusted to age. 
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After analyzing a number of studies we are able to conclude that 
hypotestosteronemia is per se associated with an increase in all-cause mortality 
irrespective of whether associated with diabetes or metabolic syndrome [105]. 
Low testosterone levels associated with or without type 2 diabetes mellitus can 
be used as a predictor for the development of cardiovascular risks and 
complications irrespective of the presence or absence of other cardiovascular 
risk factors. Hypotestosteronemia and cardiovascular disease are associated 
with common risk factors like central obesity, redistribution of fat, 
inflammatory state and coagulation abnormalities [106]. Also in patients 
presenting with hypogonadism and cardiovascular disease (CVD) the mortality 
rate appears higher when compared to men without hypotestosteronemia [107].  
Testosterone supplementation has been done to evaluate for the effects on 
the glycaemic status of men with type 2 diabetes mellitus and hypogonadism 
through many studies. But none of the studies has proven to give any conclusive 
results. Half of the studies showed no specific effect on the glycaemic status 
while half of the studies showed a definitive decrease in the glycaemic control 
with testosterone administration [108]. 
Testosterone and Insulin resistance: 
Evidences from many data have proved that hypotestosteronemia is 
associated with the development of insulin resistance. A search into the actually 
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mechanism which leads to this resistance was made by many molecular studies 
of which the most convincing was the alterations in fatty acid metabolism, 
probably due to reduced expression of the genes which are necessary in 
oxidative metabolism. Similarly it has also been proved that testosterone 
improves the insulin sensitivity directly. Thus testosterone replacement has been 
found to increase the insulin sensitivity. Also it was found that in such men who 
were receiving testosterone supplementation for hypogonadism, when the 
treatment was stopped abruptly for around 15 days the insulin sensitivity 
decreased though without much alterations in the body composition. This is an 
evidence to show that testosterone has a direct control over sensitivity of insulin 
[109]. But some reports have shown that in elderly males by bringing the 
testosterone levels into normal range, there has been a favorable effects on the 
fat distribution and hence composition thus improving the insulin sensitivity, 
but they do not have any beneficial effect on the triglyceride metabolism [110]. 
But by experimental studies it has been proved that the effect of testosterone on 
insulin resistance was an acute phenomenon and the do not produce any 
immediate effect on the body composition. At the same time, experimentally, by 
reducing the estradiol concentration and by increasing the testosterone levels for 
a period of 7 days, it has reduced the insulin resistance with beneficial effects 
on the triglyceride metabolism, and has improved the postprandial glucose-
dependent insulinotropic polypeptide (GIP) release [111]. Thus the association 
between testosterone, fat metabolism and obesity which by acting through a 
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common mechanism of increasing the proinflammatory factors, decreasing the 
insulin sensitivity thus produces endothelial dysfunction which are the essential 
factors leading to the development of cardiovascular diseases and erectile 
dysfunction (ED).  
Pathogenesis of insulin resistance: 
Present concepts throw light on the contributions of mitochondria in the 
pathogenesis of the development of insulin resistance.  Studies on animal 
models have confirmed that, in insulin resistance there is a decreased expression 
of OXPHOS genes in skeletal muscle along with the down regulation of 
peroxisome proliferator–activated receptor-γ coactivator (PGC-1α) [112].  In 
proposing the model for demonstrating the pathogenesis of insulin resistance it 
was found that there was a reduction in the peroxisome proliferator–activated 
receptor-γ coactivator expression in the presence of physical inactivity in 
genetically susceptible subjects. The decreased expression of this single protein 
led to the decreased transcription of certain genes involved in the metabolism of 
fatty acids, leading to accumulation of triglycerides in the cells of the striated 
muscles, decreased expression of mitochondrial genes with the decreased 
efficacy of  oxidative phosphorylation and resulting in insulin resistance 
ultimately. Experimental reproduction of hypogonadism has proved to show 
decreased oxidation of lipids and reduced BMR [113]. There is a positive 
relationship between the expression of the OXPHOS gene, VO2max and the levels 
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of testosterone. There are not much data to explain the direct effect exerted by 
testosterone on insulin. 
Another mechanism which is claimed in the development of insulin 
resistance is that of reduced glycogen synthetase activity [114] in experimental 
rats with low testosterone levels. This reduced activity of the glycogen 
synthetase [115] is computed to be the cause of the triglyceride accumulation in 
the myocytes intracellularly. The genetic model of type 2 diabetes mellitus with 
obesity is the Otsuka Long Evans Fatty (OLETF) [116] rat, confirms the effect of 
testosterone on the mitochondrial functions. These rats having low levels of 
androgens showed a decreased expression of peroxisome proliferator–activated 
receptor-γ coactivator and beta 3 receptor, androgen receptors present in the 
adipocytes. Further there is an increased expression of uncoupling protein 1 
(UCP-1) and up regulation of its genes. All these lead to decreased peripheral 
utilization of energy, its accumulation as fats and therefore obesity [115]. When 
these OLETF rats were supplemented with testosterone (DHEA) for 2 weeks, it 
caused many positive effects in the form of improved insulin sensitivity, 
reduction of weight, decrease in FFA, and leptin concentration, all due to a 
considerable increase in the expression of UCP-1, β3AR, and PGC-1α [116].  
It requires further experimentations and analysis in to the expression of 
genes in the skeletal muscle with testosterone replacement. If the expression of 
the OXPHOS gene is found to be definitively modified by testosterone then 
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surely testosterone has a bright future in the prevention and treatment of type 2 
diabetes mellitus in men with hypogonadism. 
Testosterone and Metabolic syndrome: 
Presently there have been many studies proving the correlation of 
metabolic syndrome and hypotestosteronemia. Such men have a reduced 
concentration of TT, FT, and SHBG [117]. This syndrome which includes an 
alteration in a number of metabolic parameters has an increased risk of 
mortality more so when the patient do have associated low levels of 
testosterone. There is a resulting proinflammatory state which leads to 
endothelial dysfunction and other complications like cardiovascular disease and 
ED. On the other hand, hypotestosteronemia can be used as a predictor for the 
future   development of syndrome X and type 2 diabetes mellitus.  
 Low levels of serum total testosterone cause redistribution of fat and 
further accumulation of intra-abdominal fat thus leading to central obesity [118]. 
Independent of the age factor or the presence of obesity a low testosterone 
levels are associated with the development of metabolic syndrome. 
Experimentally suppression of testosterone in men caused an increase in the 
body fat [119]. The same effect occurs when there is a decrease in the 
concentration of sex hormone binding globulin. Since obesity is found to 
decrease the levels of both the sex hormone binding globulin and the total 
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testosterone SHBG is a confounding factor in defining the correlation between 
hypotestosteronemia and obesity [120].  
There are a number of factors which determine the presence of 
hypotestosteronemia or low levels of sex hormone binding globulin. These 
include age, race, and obesity. But hypotestosteronemia is associated with type 
2 diabetes mellitus independent of these factors or the diagnostic criteria of 
diabetes [121]. Studies also prove that TT, FT, and sex hormone binding globulin 
independently can be used in the prediction of the development of type 2 
diabetes. [122]   There is an emerging interest on SHBG as an independent 
positive predictor of diabetes mellitus. But some recent studies have proved that 
free testosterone cannot be useful for this purpose [124]. As mentioned above 
SHBG is a confounding factor for the association of hypotestosteronemia and 
type 2 diabetes mellitus and since most cases of diabetes are associated with 
obesity, obesity also remains confounding to establish this relationship. 
Compared to non-diabetic men reduced free testosterone concentrations are 
more prevalent in diabetic men [123]. Also, low SHBG was found to be a strong 
independent predictor of type 2 diabetes mellitus [124]. Finally, in prospective 
studies, androgen deprivation therapy either using bilateral orchidectomy or 
gonadotropin-releasing hormone agonist in older men with prostate cancer is 
associated with an increased risk of diabetes and CVD [125].  
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Pathobiology of low testosterone in type 2 diabetes  
Adipocyte is biologically active tissue secreting a number of substances 
cytokines and chemokines. Some of them include adipokines, tumor necrosis 
factor (TNF)-α, interleukin (IL)-6, IL-1β, VEGF, transforming growth factors, 
plasminogen activator inhibitor-1, and angiotensinogen [126]. All of these factors 
are mediators in inflammation. Thus there is an inflammatory state which is set 
up in the body milieu.  When the amount of the adipose tissue increases as it 
occurs in obesity, there is a chronic proinflammatory state set up in the body 
which results in increased concentration of inflammatory mediators as well as 
FFA and an increased estrogens output from the adipose tissue, which is 
obtained by its conversion from testosterone. This state of chronic inflammation 
leads to alteration in the blood mechanics with stiffness of the vasculature and 
endothelial dysfunction. All these together results in systemic inflammation and 
contributes to the development of metabolic syndrome and type 2 diabetes 
mellitus as well as hypotestosteronemia.  
The proposed mechanism of how obesity and inflammation promotes 
insulin resistance is through the release of excess of FFA. This in turn through 
the nuclear factor-κB pathways produces augmented synthesis of TNF-α, 
interleukin 6 and MCP-1. The former factor causes increased lipolysis and 
formation of excess of free fatty acid while the latter factors cause more and 
more recruitment of other inflammatory cells and all these alters the sensitivity 
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of insulin. Other mechanism of actions of these inflammatory mediators is an 
increased expression of the adhesion molecules in the endothelium of the blood 
vessels and also in its smooth muscles mediated by TNF-α. Apart from this 
TNF-α also causes a dysregulation between the vasoconstriction mediated by 
ET-1 and the vaso relaxtion induced by nitric oxide ultimately favouring 
vasoconstriction; similarly CRP, though nonspecific, a marker of inflammation 
IL-6 is increased through IL-6 mediated enhanced hepatic synthesis. 
Adipokines, [127] another important mediator modulates chemotaxis and 
adhesion of inflammatory cells especially monocytes and facilitates its 
conversion in to macrophages.  
Normally the conversion of testosterone to estrogen [83] occurs in the 
adipocytes because the enzyme aromatase is located in the fat cells. In the 
presence of obesity the amount of fat tissue mass that can act as a site for this 
conversion increases and hence there is more aromatisation reaction taking 
place thereby decreasing the serum level of testosterone due to its excessive 
conversion in to estrogen in the adipocytes. This in turn activates the 
hypothalamic E2 receptors and produces feedback inhibition of the gonads. 
Thus aromatase inhibitors play a role in attenuating the symptoms of 
hypogonadism in obese men [128].  
 
52
Testosterone and atherogenesis: 
Testosterone has an antithrombotic effect on the clotting mechanism. 
There is an inverse relationship between the prothrombotic clotting factors, 
fibrinogen and the tissue plasminogen activator inhibitor 1. It also has a direct 
relationship with the plasminogen activator activity [129]. Thus the presence of 
normal levels of testosterone concentrations is necessary for maintaining proper 
blood homeostasis.  
 
 
From experimental studies it has become evident that testosterone slows down 
the atherogenesis [130]. Iatrogenic orchidectomy in mouse led to the development 
of atherosclerotic plaques in the aorta. Another important point to be noted is 
that, irrespective of the lipid profile, testosterone slows down the progress of 
atherosclerosis. Testosterone replacement therapy has thus retarted 
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atherogenesis [131] and the further development of cardiovascular risk. By 
inhibition of the inflammatory mediators testosterone reverses prothrombotic 
environment. Testosterone reduces the early progression of atherosclerosis by a 
major mechanism by which it gets converted to estradiol in the walls of the 
blood vessel by the reaction of aromatization. This can be proved by the 
increase in the progression of atherosclerosis in patients on aromatase 
inhibitors. 
Testosterone Levels and Cardiovascular Disease (CVD) 
It was initially presumed that high levels of testosterone produce adverse 
effects on the heart and the vascular system. But latter there was a consensus 
that high normal range of testosterone level did not produce any risk to the 
cardiovascular system. Presently it has been found through many meta-analyses 
that lower levels of testosterone are associated with a stronger positive 
correlation to the development of adverse cardiovascular effects. The most 
important effects by which hypotestosteronemia can induce atherosclerosis and 
hence coronary artery disease includes alteration of hemostatic mechanics 
towards a prothrombotic as well as a fibrinolytic state, increased insulin 
resistance along with an adverse lipid profile [132].  It has also been proven by 
experimental studies that castration of the testes resulted in increased risk of 
atherosclerosis whereas testosterone administration diminished the risk. 
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Apart from decreasing the adverse cardiac effects testosterone also has 
many beneficial effects on the heart. Testosterone has a strong vaso-relaxing 
effect on the coronary vasculature [133]. This effect is caused by testosterone 
induced calcium channel blockade in the smooth muscles of the blood vessels. 
This action of testosterone has been used to raise the threshold of angina in men 
with hypotestosteronemia thereby decreasing the development of angina [134]. 
Testosterone is also beneficial in the treatment of chronic congestive heart 
failure by increasing the functional capacity and by improving the insulin 
sensitivity. [135]  
With the knowledge of the available studies it can be thus concluded that 
for optimal cardiovascular health it is always necessary to maintain the level of 
plasma testosterone about the mid-range of the normal values. It has also been 
shown that testosterone levels both below or above the normal values pertaining 
the particular age has found to raise the cardiovascular risks especially [136]. 
Thus is the need for maintaining a normal testosterone level to prevent 
increased cardiovascular mortality. 
In summary, hypotestosteronemia has a definitive risk on the 
cardiovascular wellbeing. By producing adverse effects on various metabolic 
parameters they increase the risk and create a pro inflammatory, prothrombotic 
state promoting atherogenesis. All these effects can be reversed by testosterone 
replacement therapy. The coronary vasodilatory effect has been claimed for the 
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improvement that it produces in angina thereby reducing myocardial ischemia 
[137]. Recent studies have shown that the use of testosterone administration in the 
improvement of chronic heart failure [138]. Thus it has been found by recent 
studies that the mortality rates in men from cardiovascular death are much more 
in men with hypotestosteronemia rather than men with a normal range of serum 
testosterone level. 
TESTOSTERONE REPLACEMENT THERAPY: 
The aim of testosterone replacement therapy is to produces symptomatic 
relief in patients with hypogonadism. This is achieved by bringing the 
testosterone levels to near normal with the help of exogenous synthetic 
hormones. With the emergence of novel methods for the delivery of testosterone 
these have become possible [139]. Some of the newer modes of testosterone 
delivery include 1% testosterone gel, transdermal testosterone patch, buccal, 
bioadhesive, T tablets, testosterone pellets, testosterone-inadhesive matrix patch 
[140] and depot intramuscular injections. Further moving one step ahead, 
testosterone replacement in patients with type 2 diabetes mellitus who suffer 
from hypotestosteronemia, there is multiplicity of benefits. Apart from relief of 
symptoms pertaining to hypogonadism and stabilization of glycemic control, it 
also has a positive effect on the following: reduction of blood pressure, 
normalization of the lipid profile with reduction in the obesity and other 
metabolic parameters [141]. Further perspective is that either in normal or in 
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diabetic men, testosterone increases the insulin sensitivity in patients with 
hypogonadism. Furthermore studies have proved that there is a marked 
reduction in the insulin resistance in diabetic men with hypotestosteronism [142]. 
Similarly in patients with chronic congestive cardiac failure, it has been found 
that insulin resistance is a common entity. Thus administration of testosterone in 
such patients has decreased the insulin resistance. Thus it is evident that 
testosterone improves the insulin sensitivity, irrespective of whether an 
individual has glucose intolerance or not. 
The important mediators involved in producing insulin resistance are 
proposed to be the inflammatory cytokines i.e. interleukins 1 beta and 6, tumor 
necrotic factor alpha etc. Testosterone has been found to decrease the synthesis 
of these inflammatory mediators, thereby improving the insulin sensitivity. And 
also organs involved in insulin resistance like the liver, adipose tissue and 
muscles are affected by testosterone. By these mechanisms testosterone 
produces a decline in insulin resistance.  
Another important aspect of testosterone treatment is that it decreases body 
fat and thereby the body mass index and waist and hip circumference in men 
with hypogonadism, irrespective of whether they are obese or not [143].  These 
parameter are one of the important markers for the development of metabolic 
syndrome or syndrome X, which in turn is the main risk factor for the 
development of atherosclerotic diseases, especially coronary artery disease and 
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stroke. Similarly central obesity which is considered one of the markers for the 
metabolic syndrome has been found to decrease after testosterone replacement. 
Another factor, the Leptin is related to body fat amount. In patients with 
metabolic syndrome and hypogonadism treatment with testosterone has shown 
to decrease the leptin levels [144].  
Testosterone also affects the lipid profile positively. This has been proved 
by many studies undertaken in patients with metabolic syndrome. These studies 
have shown that testosterone replacement have shown to produce a considerable 
fall in the total cholesterol levels. It also produces a small though significant fall 
in the LDL cholesterol [145]. But the effect of testosterone on the HDL 
cholesterol is not predictable; it may show an increase, decrease or may even 
remain unchanged. Some studies have also shown that after an initial reduction 
in HDL cholesterol, it rises back to its previous values. The triglyceride levels 
remain unchanged with testosterone therapy. Another important lipid fraction 
which has been presently given more importance due to its strong positive 
relation with coronary heart disease [146] is Lipoprotein a, Lp(a). It is associated 
with especially premature coronary artery disease than the other lipid fractions. 
It has been found that, in patients with hypotestosteronemia with syndrome X or 
with diabetes mellitus this testosterone replacement therapy has found to 
produce a significant reduction in Lipoprotein a, Lp (a) level, thereby reducing 
the cardiovascular risks. 
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Another important aspect is that there are a number of studies done on the 
testosterone replacement therapy, but it has not proved by any of the studies that 
testosterone administration has produced any adverse cardiovascular accidents, 
cardiac risks or has produced increased mortality. All these are favorable for the 
future developments in this field of treatment. 
To summarize testosterone replacement has produced a significant decline 
in the cardiovascular risk factors [147],  such as improving insulin sensitivity, 
stabilizing the glycemic levels, maintaining normal blood pressure, reducing 
central obesity, normalizing the lipid profile and reducing the inflammatory 
state in which the body ensues apart from maintaining the sexual functions.  
Testosterone in Diabetic foot: 
Sensory motor neuropathy, foot ulcers, peripheral vascular disease and 
infections are the most common cause of lower limb complications in diabetes 
mellitus [148]. Infections in the foot are the commonest cause of limb amputation 
in diabetic patients. Ulcerations in the foot are mainly due to 1) Peripheral 
vascular disease 2) Sensory neuropathy 3) Repeated minor trauma to the foot 4) 
Arch abnormalities. These complications of the foot improve well with 
testosterone administration. 
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These beneficial effects may be due to: 
1) Testosterone increases the haemoglobin concentration by stimulating 
erythropoiesis. 
 2) Studies have shown that there is a relation between testosterone levels and 
peripheral vascular disease [149].  This is mainly due to the action of testosterone 
on the vascular smooth muscles.  Testosterone causes vasodilatation mainly 
through smooth muscle relaxation, which does not require the endothelium, 
although an endothelium may contribute as shown by few studies [150]. Although 
the precise mechanism that causes this vasodilatory effect is still on debate, the 
proposed  mechanism is either due to the activation of K (+) channels or due to 
the of Ca (2+) channels blockage in the myocytes of the blood vessels[151]. 
Knowledge of this action of testosterone paves way for the utilisation of 
testosterone replacement therapy [152] in the healing of diabetic foot ulcers. 
Testosterone administration improves the vascular integrity and functions. 
Along with its vasodilatory effect testosterone improves the local oxygen 
pressure in the blood vessels thereby improving the vascular functions and 
promoting the healing of ulcers. 
3) The anabolic action of testosterone through its protein synthesizing capacity 
also is responsible for its beneficial effect in addition to its effects on the 
vasculature [153].  
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4) Testosterone also has effect on the platelets and clotting mechanism. In 
experimental studies androgens are found to inhibit the aggregation of platelets 
mainly induced by oxidative stresses. This is due to the decreased release of 
thromboxane A (2) from the platelets [154]. Testosterone also affects the 
fibrinolytic pathway positively. As a result of these mechanism the blood flow 
to the foot microvasculature increases thereby promoting wound healing. 
5) The present model for the origin and progression of atherosclerosis and hence 
cardiovascular diseases is the response-to-injury hypothesis. According to this 
hypothesis atherosclerosis is a chronic inflammatory response of the arterial 
wall to endothelial injury. Inflammation is therefore a key factor in the 
development of coronary heart diseases [155]. Treatment with testosterone has 
found to show a decrease in the inflammatory mediators which are involved in 
this process. In doing so it regulates the integrity and function of the 
endothelium. [156].  
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MATERIALS AND METHODS 
STUDY DESIGN 
 Case control study 
STUDY CENTRE 
 Government General Hospital, Chengalpattu 
SELECTION OF PATIENTS 
1. INCLUSION CRITERIA 
1. Men with type 2 Diabetes Mellitus between the age of 35-75yrs 
2. Men with no H/O Diabetes Mellitus with FBS < 126 mg/dl between 
the age of 35-75yrs 
2. EXCLUSION CRITERIA: 
1. Patients with Chronic Liver Disease 
2. Patients with chronic infections like HIV, TB 
3. Patient on anabolic steroids 
4. Patients on Chemotherapy or Radiotherapy 
5. Patients with Primary Hypogonadism 
3. SAMPLE SIZE 
 100 patients with Type 2 Diabetes Mellitus between the age of 
35-75yrs  
 100 non diabetic men of the same age group  
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MATERIALS AND METHODS 
 
METHODOLOGY: 
We started the study with the selection of cases and controls. We selected 
100 diabetic men from our Diabetology OPD, Chengalpattu Medical College 
who fitted in to the inclusion criteria as our cases. As controls we selected 
subjects without history of diabetes mellitus whose FBS was less than 126 
mg/dl on two occasions, from our male Medical OP. Informed consent was 
obtained from all subjects. A detailed history regarding the duration of diabetes, 
the patients other associated risk factors like hypertension, coronary artery 
disease was obtained. Anthropometric measurements like height, weight, waist 
and hip circumferences were measured. BMI was calculated by obtaining the 
ratio of the weight and the square of height (kg/m²). Waist-Hip ratio was also 
calculated. Fasting blood sugar and postprandial blood sugar were measured 
using chromatography method. Total cholesterol was also measured. Total 
testosterone in the early morning (8:00–10:00 AM) was measured using CLIA 
(Chemiluminescence enzyme immunoassay)  method. The normal range for 
early morning total testosterone in adult males is considered between 300ng/dl 
and 900ng/dl. 
The average serum testosterone levels were compared between the 
diabetic and non-diabetic men and was statistically analysed. The diabetic 
patients were further grouped based on the duration of diabetes, BMI, 
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cholesterol levels and presence or absence of associated risk factor and 
analysed. 
 
STATISTICAL ANALYSIS: 
 
The T-test for independent samples was used. 
 
 
DATA COLLECTION AND ANALYSIS 
Collection of data: As per Performa attached. 
Analysis of data: Using statistical package SPSS software 
Conflict of interest: NIL 
Financial support: NIL 
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OBSERVATIONS AND RESULTS  
  
 We conducted the study from April 2012 to September 2012 and we 
analyzed 100 diabetic and 100 non diabetic men from whom samples were 
collected for the estimation of serum levels of total testosterone. 
 
Among the diabetic men, the average testosterone values were calculated 
and grouped according to the age categories. 
 
Table 1: Testosterone levels according to age group in diabetic men 
 
 
 
 
S.No Age (yrs.) No of subjects Avg Serum Testosterone 
(ng/dl) 
1. 35-45 15 462.73 
2. 46-55 51 307.51 
3. 56-65 27 267.41 
4. 66-75 07 211.14 
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Figure 1: Testosterone levels according to age group in diabetic men 
 
Similarly average testosterone was calculated for the non-diabetic men and 
grouped. 
Table 2: Testosterone levels according to age group in non-diabetic men 
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S.No Age (yrs) No of subjects Avg Serum Testosterone 
(ng/dl) 
1. 35-45 15 655.53 
2. 46-55 50 620.46 
3. 56-65 25 532.30 
4. 66-75 10 480.00 
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Figure 2: Testosterone levels according to age group in non-diabetic men 
 
 
 On comparing the testosterone level we found that, there was a significant 
decrease in the testosterone levels between the diabetics and non-diabetics in 
each age group. 
Table 3: Comparison of the total testosterone levels between diabetics and        
non-diabetics 
 
S.No Group 35-45yrs 46-55yrs 56-65yrs 66-75yrs
1. Diabetic men 462.73 307.51 267.41 211.14 
2. Non-diabetic men 655.53 620.46 532.30 480.00 
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Figure 3: Comparison of the testosterone levels between diabetics and            
                 non-diabetics 
 
 
 
 
 
Figure 4: Comparison of the testosterone levels between diabetics and            
                 non- diabetic 
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Statistical analysis was done with the student T test for independent 
samples. P values where calculated for each age group. 
 
 
Table 4: P values for different age groups 
 
S.NO Age group (yrs) Diabetics TT 
(ng/dl) 
Non-Diabetics TT 
(ng/dl) 
P value 
1. 35-45 462.73 655.53 0.028 
2. 46-55 307.51 620.46 0.01 
3. 56-65 267.41 532.30 0.001 
4. 66-75 211.14 480.00 0.001 
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SPSS Output 
35‐45yrs: 
 
T-Test 
  
Group Statistics 
 
 Code N Mean Std. Deviation 
Std. Error 
Mean 
Stlevel Diabetic 15 462.73 125.238 32.336 
Non Diabetic 15 655.53 136.471 35.237 
 
  
 
 
 
 
Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
    F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. 
Error 
Differen
ce 
95% Confidence 
Interval of the 
Difference 
    Lower Upper Lower Upper Lower Upper Lower Upper Lower 
Stleve
l 
Equal 
variances 
assumed 
1.631 .212 -7.723 28 .028 -369.333 47.825 
-
467.29
9 
-
271.36
8
  Equal 
variances 
not 
assumed 
    -7.723 27.796 .028 -369.333 47.825 
-
467.33
1 
-
271.33
5
 
 
46‐55yrs: 
T-Test 
Group Statistics 
 
  Code1 N Mean Std. Deviation 
Std. Error 
Mean 
Stlevel1 Diabetic 51 307.51 108.389 15.177 
Non Diabetic 50 620.46 91.755 12.976 
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Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
    F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
    Lower Upper Lower Upper Lower Upper Lower Upper Lower 
Stlevel1 Equal 
variances 
assumed 
2.061 .154 -16.646 99 .001 -332.950 20.001 
-
372.637 
-
293.263
  Equal 
variances 
not 
assumed 
    -16.674 96.952 .001 -332.950 19.968 
-
372.582 
-
293.318
 
 
 
56‐65yrs: 
T-Test 
Group Statistics 
 
 Code2 N Mean Std. Deviation 
Std. Error 
Mean 
Stlevel2 Diabetic 27 267.41 93.777 18.047 
Non Diabetic 25 532.30 170.914 34.183 
 
 
 
 
 
 
Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
    F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
    Lower Upper Lower Upper Lower Upper Lower Upper Lower 
Stlevel2 Equal 
variances 
assumed 
.687 .411 -6.999 50 .0001 -264.893 37.848 
-
340.912 
-
188.873
  Equal 
variances 
not 
assumed 
    -6.853 36.618 .0001 -264.893 38.655 
-
343.242 
-
186.543
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66‐75yrs: 
T-Test 
Group Statistics 
 
 Code3 N Mean Std. Deviation 
Std. Error 
Mean 
Stlevel3 Diabetic 7 211.14 66.261 25.044 
Non Diabetic 10 480.00 168.419 53.259 
 
 
 
 
 
Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
    F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
    Lower Upper Lower Upper Lower Upper Lower Upper Lower 
Stlevel3 Equal 
variances 
assumed 
5.724 .030 -5.462 15 .001 -368.857 67.526 
-
512.785 
-
224.930
  Equal 
variances 
not 
assumed 
    -6.267 12.503 .001 -368.857 58.853 
-
496.518 
-
241.197
 
 
 
We analyzed the other associated factors in the diabetic men. We grouped 
the duration of diabetes and analyzed the testosterone levels and compared 
them. 
 
 
 
 
72
 
Table 5: Testosterone levels according to the duration of diabetes 
 
S.No Duration of Diabetes No of subjects Avg Serum Testosterone 
(ng/dl) 
1. <1yr 8 541.62 
2. 1-5yrs 49 339.06 
3. 6-10yrs 20 259.85 
4. 11-15yrs 11 257.01 
5. >15yrs 12 206.33 
 
Figure 5: Testosterone levels according to the duration of diabetes 
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 Body mass index was calculated by obtaining the ratio of the weight and 
the square of height (kg/m²).  The testosterone levels were then compared 
between the different BMI.    
 
Table 6: Testosterone levels according to the Body Mass Index 
 
S.No BMI No of subjects Avg Serum Testosterone 
(ng/dl) 
1. 18-24.9 57 368.70 
2. 25-29.9 29 258.51 
3. >30 14 226.64 
 
Figure 6: Testosterone levels according to the Body Mass Index 
 
18‐24.9
25‐29.9
>30
74
 Also the waist - hip ratio was calculated and the testosterone levels were 
compared. 
 
Table 7:  Testosterone levels according to the Waist-Hip ratio 
 
S.No W/H ratio No of subjects Avg Serum Testosterone 
(ng/dl) 
1. <0.8 57 368.71 
2. >0.9 43 248.14 
 
Figure 7: Testosterone levels according to the Waist-Hip ratio 
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There other risk factors such as hypertension, cardiovascular diseases were also 
analyzed. Those diabetic men with these risk factors were separated into one 
group and those without as other group and their testosterone levels were 
compared. 
 
 
Tables 8: Testosterone levels according to the presence or absence of other 
risk  factors. 
 
S.No Associated Risk factors No of subjects Avg Serum Testosterone 
(ng/dl) 
1. Present 51 257.17 
2. Absent 49 374.18 
 
 
 
Figure 8: Testosterone levels according to the presence or absence of other 
risk factors. 
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 The testosterone levels were then compared according to the cholesterol 
levels in the diabetic men and were separated in to different group, according to 
the cholesterol levels as < 200 mg/dl to be normal, 200-240mg/dl as moderate 
risk and >240 mg/dl as high. 
 
Table 9: Testosterone levels according to the serum Cholesterol 
 
S.No Serum Cholesterol 
(mg/dl) 
No of subjects Avg Serum Testosterone 
(ng/dl) 
1. <200 38 4.184 
2. 200-240 47 2.604 
3. >240 15 2.082 
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Figure 9: Testosterone levels according to the serum Cholesterol 
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DISCUSSION 
 
Diabetes Mellitus which was once considered as a disease of minor 
significance has now become one of the major epidemic and a global health 
problem. It is one of the most common non- communicable diseases globally, 
with around 290 million people suffering from diabetes worldwide. The 
proportion of diabetes in India is steadily on a rise and in another fifteen years 
India would have the largest number of diabetics in the world. It has been well 
known about the most dreaded micro-vascular and macro-vascular 
complications of diabetes mellitus but the other endocrinological perspectives 
of diabetes are often not given importance.  
Our study was conducted in Chengalpattu Government Medical College 
Diabetology OPD which caters around 300 patients per day as outpatients. 100 
diabetic men and 100 non diabetic men were selected and serum total 
testosterone assay was done. Average testosterone values were calculated for 
different age groups. The results were then compared age-wise and the patterns 
of testosterone in each age group were analyzed in diabetic and non-diabetic 
men. The average testosterone values between the diabetic and non-diabetic 
men in the age group of 35-45yrs was 462.73ng/dl and 655.53ng/dl 
respectively, in the age group of 46-55yrs was 307.51ng/dl and 620.46ng/dl 
respectively, in the age of 56-65yrs was 267.41ng/dl and 532.3ng/dl 
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respectively, in the age group 66-75yrs was 211.14ng/dl and 480ng/dl 
respectively.   
Statistical analysis was made and the P values were calculated by the 
student T- test. The association between the diabetic and non-diabetic in each 
age group was found to be significant with a P-value of <0.05. Thus the 
decrease in the serum level of testosterone is found to be significant. We also 
found that as the age progresses, there is a steady decline in the serum levels of 
testosterone in both the groups. But the fall in the testosterone values is much 
more significant in the diabetics. 
We did the second part of the study, where we divided the diabetic men 
into smaller sub groups and compared different parameters. Firstly according to 
the duration of diabetes we grouped the patients. We found in our study that, as 
the duration of diabetes increases the fall in the serum testosterone level became 
more significant with around normal values up to 5yrs of diabetes and later 
declining. 
The next parameter we evaluated was the Body mass index and Waist hip 
ratio. In both the groups we found that as the BMI and the W/H ratio increases 
there is a decrease in the serum levels of testosterone, thereby suggesting an 
inverse relation between these parameters and testosterone levels. 
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The other parameters we evaluated were, to compare the effects of other 
risk factors. Out of these, we considered risk factors like hypertension or 
coronary artery disease and grouped them into those with risk factors and those 
without. We compared the testosterone values between these two groups and 
found that, there was a decline in the serum testosterone values in patients with 
associated other risk factors than those without risk factors.  
Finally we segregated the diabetic patient with different levels of serum 
cholesterol and separated them in to three groups and found that this relation to 
be inverse, that is as the serum cholesterol levels increases the serum 
testosterone level decreases with a normal level of 4.1mg/dl when the 
cholesterol is <200mg/dl and values of around 2.08mg/dl when cholesterol is 
>250mg/dl. 
Thus we also evaluated the effects of multiple risk factors on diabetic men 
and testosterone levels. 
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CONCLUSION 
  
Thus we conclude that there is a significant reduction in the levels of 
serum testosterone in diabetic men as compared to that of non-diabetic men. 
Even though the declining trend of the testosterone levels occurs as the age 
increases, the reduction in the testosterone levels are more significant in the 
diabetic group as compared to that of the non-diabetic men. Thus from our 
study, we propose that age factor alone is not the cause of hypotestosteronemia 
in diabetic men. 
 From the analyses of different factors like BMI, cholesterol and other risk 
factors we have shown the influence of multiple factors on the levels of 
testosterone, in which most of them has an inverse correlation. 
 Thus, in diabetic patients, hypotestosteronemia is a common entity. 
Though the symptoms of low testosterone are non-specific, a detailed 
symptomatic analysis would pave way to bring to light this hidden epidemic. 
Hence we suggest the measurement of testosterone in patients with diabetes, as 
the replacement of testosterone can have multiple benefits in diabetic patient to 
prevent diabetic complication and cardiovascular diseases. 
 Testosterone level can further predict the development of type 2 diabetes 
mellitus, the utilization of this aspect of testosterone in future, is not too far. 
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LIMITATIONS 
 
This study has the following limitations: 
1. The level of sex hormone binding globulin, which is a confounding 
factor, was not calculated. 
2. The level of free testosterone was not computed. 
3. The actual duration of diabetes may not be accurate. 
 
 
 
 
 
 
 
 
 
 
 
83 
 
ABBREVIATIONS 
T             Testosterone 
FT             Free Testosterone 
TT                      Total Testosterone 
DHT                      Dihydrotestosterone 
DHEA                     Dehydroepiandrsterone 
SHBG                     Sex hormone–binding globulin 
GnRH                    Gonadotrophin releasing hormone 
FSH                    Follicle stimulating hormone 
LH                  Luteinizing hormone 
AR                   Androgen receptor 
T2DM                   Type 2 diabetes mellitus 
CRP                      C reactive protein 
BMI                       Body mass index 
W/H                     Waist hip ratio 
kDa                       Kilo dalton 
DNA                    Deoxy ribonucleic acid 
84 
 
RNA                      Ribonucleic acid 
RNAP                   Ribonucleic acid polymerase 
BMD                    Bone mineral density 
ED                      Erectile dysfunction 
LC-MS                 Liquid chromatography tandem mass spectrometry  
HPLC                High-performance liquid chromatography  
MS                     Mass spectrometry 
hCG                  Human chorionic gonadotropin 
MIS                   Mullerian inhibiting substance 
CVD                 Cardiovascular disesase 
Lp(a)                    Lipoprotein A 
TNF                 Tumor necrotic factor 
IL                     Interleukins 
PCG                 Peroxisome proliferator–activated receptor-γ coactivator 
OXPHOS           Oxidative phosphorylation 
OLETF              Otsuka Long Evans Fatty  
FFA                    Free fatty acid 
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PROFORMA 
Name    : 
Age    : 
Sex    : 
Occupation   : 
Marital status  : 
Address   : 
IP. No   :  
BRIEF PATIENT HISTORY: 
Duration of Diabetes    : 
H/o any Chemotherapy or Radiation   : 
H/o any chronic medical illness   : 
High risk behavior     : 
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 DURATION MEDICATIONS 
DIABETES MELLITUS   
SYSTEMIC HYPERTENSION  
CORONARY ARTERY DISEASE   
 
 
HABITS DURATION QUANTITY 
Smoking   
Alcoholism   
 
 
FAMILY H/O Father Mother Siblings 
DIABETES MELLITUS    
SYSTEMIC HYPERTENSION    
CORONARY ARTERY DISEASE    
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PHYSICAL EXAMINATION 
MEASUREMENTS: 
Height   : 
Weight   : 
Waist circumference : 
Hip circumference  : 
BODY MASS INDEX : 
WAIST HIP RATIO :  
GENERAL EXAMINATION 
VITAL SIGNS         
  Pulse Rate  : 
  Blood Pressure      :    
  Respiratory rate : 
                   Temperature  : 
CARDIOVASCULAR SYSTEM : 
RESPIRATORY SYSTEM  : 
GASTROINTESTINAL SYSTEM : 
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CENTRAL NERVOUS SYSTEM : 
                INVESTIGATIONS 
CBC 
 TC 
 DC 
 HB 
 HEMATOCRIT 
 ESR 
 PLATELETS 
LFT 
 TOTAL BILIRUBIN 
 AST 
 ALT 
 SAP 
 TOTAL PROTEIN 
RFT                     
         BLOOD SUGAR- FBS 
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            PPBS 
 UREA 
 SERUM CREATININE 
 Na+ 
 K+ 
FASTING LIPID PROFILE 
SERUM TESTOSTERONE 
HIV    : 
USG ABDOMEN  : 
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PATIENT CONSENT FORM 
STUDY DETAIL 
“STUDY OF TESTOSTERONE LEVELS IN MEN WITH TYPE 2 DIABETES 
MELLITUS” 
STUDY CENTRE  :   Chengalpattu Medical College and Government General Hospital. 
PATIENTS NAME  : 
PATIENTS AGE   : 
IDENTIFICATION NUMBER        : 
   Patient may check (     ) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to ask 
question and all my questions and doubts have been answered to my complete satisfaction.   
I understand that my participation in the study is voluntary and that I am free to withdraw at any time without 
giving reason, without my legal rights being affected.        
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical committee and 
the regulatory authorities will not need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not to restrict the use of any data or results that 
arise from this study.          
        
I agree to take part in the above study and to comply with the instructions given during the study and faithfully 
cooperate with the study team and to immediately inform the study staff if I suffer from any deterioration in my 
health or wellbeing or any unexpected or unusual symptoms.           
I hereby consent to participate in this study.               
I hereby give permission to undergo complete clinical examination and diagnostic tests including hematological, 
biochemical, radiological tests.          
 
Signature/thumb impression:    
Patients Name and Address:                   Place     Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place     Date      
 
MASTER CHART‐ DIABETICS
S.No. Name Age Sex OP No. D.O.S. Duration of DM
Ass other RISK 
FACTORS PR BP (mm/Hg) CVS RS CNS BMI  W/H ratio
Hb (g/dl) TC (/cu.mm) DC
1 Subramani 47yrs M 1719/11 02‐04‐2012 3yrs NIL 86 120/80 N N N 20.8 0.82 16.2 4120 53/42/5
2 Veeramani 35yrs M 2362/11 02‐04‐2012 3yrs NIL 88 110/70 N N N 23.03 0.85 13.6 5500 70/28/2
3 Hariraman 38yrs M 2037/12 02‐04‐2012 6months NIL 72 130/80 N N N 25.2 0.96 14.5 6300 67/30/3
4 Meganathan  36yrs M 2043/12 02‐04‐2012 11/2 yrs NIL 86 120/70 N N N 19.5 0.78 12.8 7500 60/38/2
5 Gunasekar 57yrs M 589/07 02‐04‐2012 15yrs HTN 90 120/80 N N N 20.68 0.81 14.7 4340 72/27/1
6 Thambiraj 75yrs M 753/10 02‐04‐2012 2yrs NIL 82 120/80 N N N 26.8 0.97 13.7 6700 76/22/2
7 Ellapan 52yrs M 2040/12 02‐04‐2012 4yrs HTN 80 90/60 N N N 25.24 0.96 14.6 7800 71/26/3
8 Mani 50yrs M 1696/12 02‐04‐2012 6months NIL 96 120/80 N N N 22.8 0.84 16 6000 70/26/4
9 Elumalai 52yrs M 19/2011 16‐04‐2012 6yrs CAD  80 130/80 N N N 27.8 0.98 15.7 4700 60/39/1
10 Anamalai 55yrs M 1315/09 16‐04‐2012 3yrs HTN 88 120/80 N N N 22.22 0.86 14.2 4120 53/42/5
11 Venkatesan 65yrs M 169/02 16‐04‐2012 10yrs CAD/HTN 90 100/70 N N N 37.25 1.33 13.8 7500 60/38/2
12 Elangovan 48yrs M 89/05 16‐04‐2012 20yrs CAD/HTN 86 110/80 N N N 21.77 0.82 11.7 4340 72/27/1
13 Susairaj 60yrs M 1175/06 16‐04‐2012 10yrs HTN 82 100/60 N N N 30.9 1.02 9.2 4120 53/42/5
14 Paranjothi 68yrs M 160/03 16‐04‐2012 9yrs NIL 72 130/90 N N N 20.8 0.81 13.7 6700 76/22/2
15 Ramanujam 48yrs M 1592/11 16‐04‐2012 1yr NIL 88 90/60 N N N 23.3 0.89 11.6 7800 71/26/3
16 Arun 38yrs M 2047/12 16‐04‐2012 6months NIL 82 130/90 N N N 25.2 0.96 13.4 4500 68/30/2
17 Satish 40yrs M 2015/12 07‐05‐2012 1yr NIL 88 120/80 N N N 25.7 0.98 13 6800 75/23/2
18 Subbaih 55yrs M 568/05 07‐05‐2012 8yrs CAD/HTN 72 110/70 N N N 31.5 1.12 10.3 9000 74/23/3
19 Ramu 46yrs M 2045/12 07‐05‐2012 6months NIL 78 90/60 N N N 25.6 0.98 10.2 6370 60/31/3
20 Verumandi 63yrs M 160/01 07‐05‐2012 17yrs CAD/HTN 80 120/80 N N N 20.8 0.82 11.3 4390 56/40/4
21 Madasamy 53yrs M 1496/09 07‐05‐2012 4yrs NIL 88 100/70 N N N 23.5 0.89 11.4 6370 49/48/3
22 Veeraiyan 55yrs M 1568/09 07‐05‐2012 5yrs HTN 84 100/60 N N N 25.8 0.98 10.8 7500 60/38/2
23 Ramaiah 65yrs M 562/02 07‐05‐2012 14yrs CAD 90 110/80 N N N 27.6 1.1 11.8 7450 68/31/1
24 Ponnaiyan 54yrs M 1150/10 07‐05‐2012 4yrs HTN 78 140/70 N N N 24.1 0.91 14 7100 60/34/1
25 Abdulkhadar 46yrs M 2030/12 21‐05‐2012 6months NIL 80 110/80 N N N 23.8 0.89 12.5 9400 75/24/1
26 Suresh 45yrs M 2053/12 21‐05‐2012 2yrs NIL 72 110/70 N N N 22.6 0.86 11.6 8390 73/26/1
27 Antony 58yrs M 1048/04 21‐05‐2012 8yrs NIL 86 110/70 N N N 24.8 0.92 10.8 7500 60/38/2
28 Basker 64yrs M 584/01 21‐05‐2012 15yrs NIL 88 120/80 N N N 20.1 0.84 11.4 6370 49/48/3
29 Ramalingam 70yrs M 894/03 21‐05‐2012 16yrs HTN 92 90/60 N N N 20.3 0.83 10.3 9000 74/23/3
30 Arunachalam 53yrs M 620/09 21‐05‐2012 4yrs CAD/HTN 84 130/80 N N N 33.4 0.98 13.6 7800 68/29/3
31 Balu 44yrs M 1184/11 21‐05‐2012 2yrs NIL 86 140/90 N N N 22.45 0.86 10.8 7500 60/38/2
32 Veerasamy 72yrs M 144/01 21‐05‐2012 20yrs CAD 86 130/80 N N N 23.02 0.86 11.4 6370 49/48/3
33 Kani 47yrs M 1050/11 04‐06‐2012 2yrs NIL 88 120/80 N N N 34.5 1.15 10.3 4100 62/34/4
34 Sekar 58yrs M 956/05 04‐06‐2012 7yrs NIL 86 140/90 N N N 32.1 0.99 13 5500 65/32/3
35 Muthu 65yrs M 546/03 04‐06‐2012 17yrs CAD/HTN 86 130/80 N N N 20.3 0.82 12.8 4700 74/24/1
36 Ragavan 60yrs M 1145/02 04‐06‐2012 10yrs NIL 90 120/60 N N N 23.33 0.91 14 7100 60/34/1
37 Vinoth  38yrs M 2016/12 04‐06‐2012 1yr NIL 78 140/70 N N N 22.8 0.92 13.6 7800 68/29/3
38 Jeeva 40yrs M 2095/11 04‐06‐2012 2yrs NIL 88 130/80 N N N 24.5 0.93 10.8 7500 60/38/2
39 Arul 46yrs M 2072/12 04‐06‐2012 1yr NIL 84 110/70 N N N 28.8 0.99 11.4 6370 49/48/3
40 Nandhakumar 49yrs M 2002/11 04‐06‐2012 3yrs NIL 100 120/80 N N N 28.6 0.98 13.5 9000 55/47/3
41 Divan 42yrs M 2044/11 18‐06‐2012 2yrs NIL 72 110/70 N N N 25.6 0.96 9.8 6110 70/26/4
42 Sundar 46yrs M 726/11 18‐06‐2012 2yrs NIL 78 140/70 N N N 23.3 0.89 10.8 7500 60/38/2
43 Vinayagam 57yrs M 693/03 18‐06‐2012 12yrs CAD/HTN 72 110/70 N N N 29.2 1.1 11.4 6370 49/48/3
44 Mayilsami 50yrs M 926/10 18‐06‐2012 3yrs NIL 80 110/80 N N N 24.2 0.92 13 5500 65/32/3
45 Harichandran 47yrs M 2026/12 18‐06‐2012 8months NIL 84 110/70 N N N 22.1 0.89 13.6 8050 67/31/2
46 Gopal 42yrs M 2028/12 18‐06‐2012 2yrs NIL 86 130/80 N N N 20.6 0.89 12.2 7390 66/32/2
47 Balan 46yrs M 2101/12 18‐06‐2012 1yr NIL 80 120/80 N N N 21.4 0.84 12 8000 68/30/2
48 Yogaraj 65yrs M 132/01 18‐06‐2012 20yrs CAD/HTN 88 110/70 N N N 32.2 1.24 11.6 7600 75/24/1
49 Sukumar 48yrs M 821/11 02‐07‐2012 2yrs NIL 92 120/80 N N N 31.75 1.1 10.8 7500 60/38/2
CBC
S.No. Name Age Sex OP No. D.O.S. Duration of DM
Ass other RISK 
FACTORS PR BP (mm/Hg) CVS RS CNS BMI  W/H ratio CBC
50 Mohan 38yrs M 2094/12 02‐07‐2012 6months NIL 64 110/70 N N N 19.2 0.79 10.3 9000 74/23/3
51 Govindaraj 52yrs M 256/10 02‐07‐2012 3yrs NIL 86 110/80 N N N 22.4 0.85 13.6 7800 68/29/3
52 Selvaraj 54yrs M 1041/07 02‐07‐2012 6yrs CAD/HTN 74 110/70 N N N 25.8 0.96 13 5500 65/32/3
53 Muniyappan 57yrs M 1542/04 02‐07‐2012 10yrs HTN 88 110/70 N N N 20.68 0.86 13.8 6110 70/26/4
54 Chinnapaji 52yrs M 1458/09 02‐07‐2012 4yrs HTN 92 100/60 N N N 26.33 0.98 11.6 5890 72/27/1
55 Muthaal 55yrs M 1552/09 02‐07‐2012 7yrs CAD/HTN 80 120/70 N N N 28.5 0.99 13.6 7800 68/29/3
56 Deivendran 49yrs M 2014/12 02‐07‐2012 1yr NIL 92 120/80 N N N 24.24 0.89 12.8 7500 60/38/2
57 Selvakumar 60yrs M 188/01 23‐07‐2012 20yrs CAD/HTN 70 100/70 N N N 27.45 1.1 13.5 9000 55/47/3
58 Pushparaj 54yrs M 1428/07 23‐07‐2012 6yrs CAD/HTN 72 110/60 N N N 34.5 1.15 12.3 6110 70/26/4
59 Arumugam 64yrs M 147/02 23‐07‐2012 15yrs NIL 86 110/80 N N N 28.4 0.99 14.6 8000 70/28//2
60 Venugopal 55yrs M 356/04 23‐07‐2012 10yrs CAD 76 100/60 N N N 23.22 0.86 15.6 4100 76/20/4
61 Kandasamy 55yrs M 1550/09 23‐07‐2012 5yrs HTN 84 110/80 N N N 22.22 0.84 14.8 9840 60/36/4
62 Vijayan 45yrs M 265/11 23‐07‐2012 2yrs NIL 90 110/70 N N N 24.18 0.92 16.2 9000 60/38/2
63 Tamilselvan 55yrs M 1520/07 23‐07‐2012 6yrs HTN 86 110/70 N N N 23.65 0.89 14 5647 71/27/2
64 Senthil 52yrs M 251/09 23‐07‐2012 4yrs HTN/CAD 78 120/80 N N N 32.5 0.99 13.6 7800 68/29/3
65 Paranthaman 52yrs M 118/02 13‐08‐2012 15yrs CAD/HTN 72 90/60 N N N 20.78 0.87 14.8 7500 60/38/2
66 Kalaiselvan 54yrs M 596/05 13‐08‐2012 10yrs CAD 80 130/80 N N N 31.75 1.1 15.5 6110 70/26/4
67 Siva 45yrs M 1849/09 13‐08‐2012 5yrs HTN 84 140/90 N N N 30.25 0.98 13.4 9840 60/36/4
68 Rajaram 48yrs M 2030/12 13‐08‐2012 1yr NIL 86 130/80 N N N 21.5 0.86 14.4 7500 60/38/2
69 Gopikannan 65yrs M 125/01 13‐08‐2012 16yrs HTN 80 120/80 N N N 24.34 0.92 15.8 6110 70/26/4
70 Inbaraj 50yrs M 1750/09 13‐08‐2012 5yrs HTN 88 140/90 N N N 26.4 0.98 13.2 9150 57/42/1
71 Dhanavel 52yrs M 1658/09 13‐08‐2012 5yrs HTN 92 130/80 N N N 28.33 0.99 11.8 8800 69/29/2
72 Poovaraghavan 55yrs M 155/09 13‐08‐2012 6yrs CAD 72 120/60 N N N 27.5 0.96 13.6 5600 68/30/2
73 Manoharan 51yrs M 1456/10 27‐08‐2012 3yrs NIL 68 140/70 N N N 23.33 0.86 15.2 6250 62/36/2
74 Velayuthan 50yrs M 152/10 27‐08‐2012 4yrs NIL 76 130/80 N N N 23.02 0.89 13.5 5800 75/24/1
75 Solomon 51yrs M 1650/09 27‐08‐2012 5yrs HTN 92 110/70 N N N 28.4 1.1 16.2 9800 76/23/1
76 Rambabu 60yrs M 254/01 27‐08‐2012 14yrs NIL 84 120/80 N N N 24.1 0.92 12.8 7900 71/27/2
77 Sathyanarayanan 55yrs M 148/09 27‐08‐2012 4yrs HTN 90 110/70 N N N 22.6 0.84 15.8 9520 70/26/4
78 Kasinathan 50yrs M 1758/10 27‐08‐2012 3yrs NIL 88 120/80 N N N 22.64 0.89 13.8 6000 60/38/2
79 Saravanan 48yrs M 2541/12 27‐08‐2012 1yr NIL 72 110/70 N N N 25.9 0.96 15.3 8500 58/42/0
80 Balakrishanan 60yrs M 132/01 27‐08‐2012 16yrs NIL 84 130/80 N N N 27.42 0.98 14 5100 62/37/1
81 Narayanan 50yrs M 2150/12 10‐09‐2012 2yrs HTN 76 120/70 N N N 20.12 0.88 13.6 9750 72/26/2
82 Mahendran 65yrs M 146/03 10‐09‐2012 15yrs HTN 86 120/80 N N N 19.5 0.79 12.7 9300 70/25/5
83 Periyasami 75yrs M 896/03 10‐09‐2012 20yrs NIL 74 120/80 N N N 27.7 0.99 15.2 5600 77/22/1
84 Chellaiyan 56yrs M 564/04 10‐09‐2012 10yrs NIL 78 90/60 N N N 32.75 1.1 13.8 6800 71/26/3
85 Nallamuthu 50yrs M 1586/10 10‐09‐2012 3yrs HTN 72 120/80 N N N 23.03 0.88 14.6 7400 67/32/1
86 Kathirvel 48yrs M 1678/12 10‐09‐2012 1yr NIL 80 130/80 N N N 19.8 0.84 16.2 7100 75/22/3
87 Sambantham 75yrs M 1584/05 10‐09‐2012 17yrs NIL 84 120/80 N N N 24.5 0.92 13.5 9300 60/37/3
88 Rajadurai 64yrs M 1426/05 10‐09‐2012 10yrs NIL 86 100/70 N N N 22.8 0.89 14 6500 72/26/2
89 Ganesh  62yrs M 1326/09 24‐09‐2012 5yrs NIL 80 110/80 N N N 21.4 0.87 13.6 7550 67/31/2
90 Vadivel 45yrs M 2147/12 24‐09‐2012 8months NIL 88 100/60 N N N 20.78 0.84 12.8 7600 60/36/4
91 Kannan 62yrs M 196/01 24‐09‐2012 18yrs HTN/CAD 92 130/90 N N N 21.77 0.92 14.6 10500 72/25/3
92 Velu 55yrs M 1245/04 24‐09‐2012 10yrs CAD/HTN 66 120/90 N N N 32.25 1.25 13.8 4550 76/22/2
93 Vignesh 55yrs M 1457/09 24‐09‐2012 5yrs HTN 86 130/90 N N N 28.66 0.99 14.2 9750 72/27/1
94 Mahadevan 50yrs M 215/10 24‐09‐2012 3yrs CAD/HTN 88 130/80 N N N 25.8 0.96 13.6 8500 70/28/2
95 Rajakumar 72yrs M 214/05 24‐09‐2012 10yrs CAD 80 120/90 N N N 24.51 0.91 14.8 6000 60/38/2
96 Jeyakumar 56yrs M 1632/09 24‐09‐2012 5yrs NIL 86 110/70 N N N 22.6 0.88 15.4 9550 68/32/0
97 Thirunavukarsu 65yrs M 456/01 24‐09‐2012 15yrs NIL 72 120/80 N N N 26.8 0.97 16 7800 70/26/4
98 Gopi 60yrs M 895/03 24‐09‐2012 11yrs NIL 76 130/90 N N N 20.5 0.86 14.2 8500 60/38/2
99 Ramamoorthy 50yrs M 1876/09 24‐09‐2012 5yrs HTN 90 120/90 N N N 26.5 0.99 13.8 7400 69/30/1
100 Elumalai 62yrs M 159/02 24‐09‐2012 12yrs CAD 86 110/70 N N N 27.8 1.15 12.8 8400 70/29/1
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TOT CHOLESTROL(mg/dl) HIV Serum Total TESTOSTERONE (ng/dl)
TB (mg/dl) DB (mg/dl) OT (IU/L) PT  (IU/L) TP (g/dl) FBS (mg/dl) PPBS (mg/dl) Urea (mg/dl) Creatine (mg/dl) Na (meq/L) K  (meq/L)
1 0.4 24 36 6 147 222 44 1.5 134 4 170 negative 424
0.9 0.3 16 27 6.5 110 140 25 0.9 141 4.5 166 negative 617
1 0.3 21 35 8.2 128 152 40 1.2 142 3.5 180 negative 312
0.9 0.2 26 29 7 169 200 42 1.4 138 3.9 188 negative 302
0.8 0.3 28 35 6.8 126 148 46 1.5 144 3.5 210 negative 343
0.9 0.4 28 29 6.9 116 140 26 1.4 134 4 238 negative 120
0.8 0.2 25 30 6.9 176 220 55 2.1 135 3.5 200 negative 302
0.8 0.2 30 35 5.8 76 134 40 1.2 141 4.5 190 negative 467
0.9 0.3 20 22 6.4 128 150 22 0.6 136 3.6 220 negative 267
1 0.4 24 36 6 147 210 44 1.2 134 4 215 negative 232
0.9 0.2 26 29 7 139 200 30 1 138 3.9 260 negative 184
0.8 0.3 28 35 6.8 165 232 46 1.6 144 3.5 225 negative 277
1 0.4 24 36 6 120 157 21 0.7 134 4 242 negative 287
0.9 0.4 28 29 6.9 176 240 54 1.8 134 4 190 negative 316
0.8 0.2 25 30 6.9 164 210 44 1.6 135 3.5 160 negative 458
1 0.4 26 24 6.4 128 160 24 0.9 140 4 155 negative 756
0.9 0.3 27 32 7 120 165 40 1.2 139 3.9 170 negative 352
0.8 0.3 23 30 6.5 144 198 46 1.4 130 3 250 negative 189
0.7 0.2 25 35 6.3 155 215 23 0.9 146 4 166 negative 525
0.8 0.2 29 31 6.6 104 130 48 1.4 140 3.8 190 negative 178
0.9 0.3 24 29 6.2 128 163 44 1.2 145 3.9 170 negative 334
0.9 0.2 26 29 7 169 230 50 1.1 138 3.9 250 negative 219
0.9 0.2 21 27 6.6 114 135 28 1 138 4.7 230 negative 264
0.9 0.3 27 31 6.6 130 160 40 1.2 133 3.5 225 negative 270
1.2 0.3 24 33 5.9 92 134 24 1 135 3.5 180 negative 415
1.2 0.3 30 44 6.5 110 140 40 1.2 140 4.7 177 negative 418
0.9 0.2 26 29 7 135 180 30 1 138 3.9 200 negative 425
0.9 0.3 24 29 6.2 120 155 44 1.2 145 3.9 160 negative 326
0.8 0.3 23 30 6.5 124 160 49 1.4 130 3.4 210 negative 224
0.6 0.1 22 27 6.2 116 140 37 1 137 3.7 255 negative 202
0.9 0.2 26 29 7 160 200 48 1.5 138 3.9 175 negative 402
0.9 0.3 24 29 6.2 155 189 44 1.2 145 3.9 220 negative 202
0.8 0.2 20 31 6.2 140 210 50 1.1 145 4.8 250 negative 337
1 0.3 26 29 6.6 180 250 28 0.8 143 4 200 negative 468
0.9 0.3 24 29 6.1 100 139 30 0.9 138 4.1 238 negative 185
0.9 0.3 27 31 6.6 119 140 42 1.1 133 3.5 180 negative 357
0.6 0.1 22 27 6.2 130 160 47 1.4 137 3.7 160 negative 512
0.9 0.2 26 29 7 147 200 50 1.8 138 3.9 170 negative 434
0.9 0.3 24 29 6.2 116 136 44 1.2 145 3.9 175 negative 330
0.7 0.2 27 31 7.4 98 130 28 0.9 141 4.2 220 negative 254
0.8 0.2 21 16 6.4 132 170 31 1.2 140 3.1 180 negative 312
0.9 0.2 26 29 7 125 156 30 1.1 138 3.9 165 negative 345
0.9 0.3 24 29 6.2 148 200 44 1.2 145 3.9 230 negative 120
1 0.3 26 29 6.6 162 220 46 1.5 143 4 190 negative 264
1.5 0.5 23 33 7 126 160 26 0.9 143 3.8 160 negative 524
0.8 0.2 40 48 6.2 105 140 47 1.2 144 3.4 166 negative 545
0.9 0.4 28 30 6.5 110 132 30 0.6 146 3.8 170 negative 502
0.9 0.3 24 35 6.9 148 215 48 1.2 139 4 260 negative 160
0.9 0.2 26 29 7 136 174 40 1.4 138 3.9 265 negative 178
LFT RFT
TOT CHOLESTROL(mg/dl) HIV Serum Total TESTOSTERONE (ng/dl)LFT RFT
0.8 0.3 23 30 6.5 124 165 39 1 130 3.4 150 negative 828
0.6 0.1 22 27 6.2 106 140 37 0.9 137 3.7 160 negative 407
1 0.3 26 29 6.6 114 132 28 0.8 143 4 220 negative 225
0.8 0.2 21 16 6.4 135 154 40 1.1 140 3.1 215 negative 304
0.9 0.2 25 30 7.5 140 186 44 1.6 144 4.1 210 negative 412
0.6 0.1 22 27 6.2 105 134 37 0.8 137 3.7 220 negative 202
0.9 0.2 26 29 7 122 156 30 0.7 138 3.9 170 negative 408
0.7 0.2 27 31 7.4 120 160 28 0.9 141 4.2 224 negative 120
0.8 0.2 21 16 6.4 110 144 31 1 140 3.1 255 negative 164
1 0.3 34 44 6.5 186 290 40 1.5 148 3.7 200 negative 342
0.9 0.3 59 68 6.4 155 240 42 1.2 137 3.8 236 negative 192
1 0.3 28 35 6.9 110 154 28 1 140 3.3 248 negative 300
0.8 0.2 34 54 6 132 166 48 1.6 140 4 180 negative 344
0.9 0.3 27 36 6.6 118 140 27 0.8 137 4.1 210 negative 315
0.6 0.1 22 27 6.2 106 136 37 0.6 137 3.7 238 negative 170
0.9 0.2 26 29 7 140 180 40 1.2 138 3.9 250 negative 120
0.8 0.2 21 16 6.4 136 164 31 1 140 3.1 220 negative 122
1 0.3 28 35 6.9 110 152 28 0.9 140 3.3 200 negative 322
0.9 0.2 26 29 7 106 143 30 0.7 138 3.9 180 negative 386
0.8 0.2 21 16 6.4 126 140 40 1.1 140 3.1 200 negative 338
1 0.4 24 35 6 124 165 31 0.9 144 4 260 negative 178
0.9 0.3 16 22 6.5 136 180 44 1.5 146 4.5 210 negative 315
1 0.3 21 36 148 198 40 1.2 139 3.5 220 negative 260
0.9 0.2 26 29 7 156 210 40 1.4 138 3.9 175 negative 424
0.8 0.3 28 35 6.8 100 136 28 0.8 130 3.5 190 negative 319
0.9 0.4 28 36 6.9 118 142 27 0.8 137 4 250 negative 206
0.8 0.2 25 29 6.9 104 136 37 1 143 3.5 220 negative 230
0.8 0.2 30 30 5.8 146 190 44 1.5 140 4.5 225 negative 285
0.9 0.3 20 24 6.4 112 130 31 0.8 144 3.6 170 negative 408
1 0.4 24 32 6 90 124 28 0.9 137 4 230 negative 298
0.9 0.2 26 30 7 120 148 30 0.7 138 3.9 224 negative 228
0.8 0.3 28 35 6.8 110 152 40 1 141 3.5 168 negative 428
1 0.4 24 31 6 104 130 37 1 140 4 200 negative 263
0.9 0.4 28 29 6.9 134 176 44 1.2 148 4 238 negative 140
0.8 0.2 25 29 6.9 180 250 48 1.8 137 3.5 242 negative 202
1 0.4 26 27 6.4 128 158 28 1 140 4 165 negative 400
0.9 0.3 27 31 7 110 146 30 1.1 140 3.9 163 negative 480
0.8 0.3 30 33 6.5 100 132 31 0.8 137 3 230 negative 226
0.9 0.2 20 44 6.2 114 138 44 1.2 143 4 215 negative 260
0.8 0.2 24 29 7 110 144 40 1.2 140 3.1 200 negative 384
0.8 0.3 26 29 7.4 124 159 38 1 144 3.7 160 negative 506
0.9 0.4 28 30 6.4 130 176 28 0.9 137 3.8 250 negative 198
1 0.4 24 27 6.5 148 200 44 1.4 138 3.3 230 negative 190
0.9 0.2 28 29 6.4 110 162 31 1 141 4 200 negative 307
0.8 0.4 25 29 6.9 120 155 37 0.9 140 4.1 192 negative 258
0.9 0.3 26 31 6 140 180 40 1.2 137 3.7 230 negative 250
0.6 0.2 27 29 6.6 124 156 42 1.2 138 3.9 200 negative 412
0.9 0.2 28 29 6 110 140 28 0.9 141 4.2 210 negative 218
0.7 0.3 24 31 7 120 145 30 0.8 140 3.8 215 negative 179
0.8 0.3 28 14 6.8 100 132 31 0.8 148 4 236 negative 189
0.6 0.1 16 18 7.8 160 196 31 1.4 147 4.3 230 negative 245
S.No. Name Age Sex OP No. D.O.S. Duration of 
DM
PR BP (mm/Hg) CVS RS CNS BMI  W/H 
ratio
Hb (g/dl) TC (/cu.mm) DC PL  (lak/cu. mm) RBS Urea Creatine Na K TB (mg/dl)
1 Diwakar  40yrs M 56586 06‐04‐2012 NIL 86 120/80 N N N 21.4 0.84 14.2 6560 72/27/2 1.38 132 26 0.8 145 3.9 0.9
2 Jegadeesan 35yrs M 50281 06‐04‐2012 NIL 88 110/70 N N N 22.4 0.84 15.6 7500 70/28/2 2.5 109 30 1 143 3.8 0.8
3 Chinnamani 43yrs M 51902 06‐04‐2012 NIL 72 130/80 N N N 20.4 0.076 12.6 6832 67/30/3 2.5 121 28 1 140 4 1
4 Venkatesan 45yrs M 56570 06‐04‐2012 NIL 86 120/70 N N N 22.4 0.86 13.5 7700 60/38/2 2 113 34 1.2 135 3.5 0.7
5 Jayaraman 40yrs M 53584 13‐04‐2012 NIL 90 120/80 N N N 23.5 0.96 15.2 4675 72/27/1 2.7 120 20 0.6 145 3.9 0.9
6 Soundaraj 42yrs M 54598 13‐04‐2012 NIL 82 120/80 N N N 20.2 0.82 13.6 6800 76/22/2 2 92 19 0.9 146 4.2 1
7 Kumar 38yrs M 56521 13‐04‐2012 NIL 80 90/60 N N N 20.6 0.86 14.2 7900 71/26/3 1.2 78 26 1 145 3.5 0.7
8 Suresh 40yrs M 52551 13‐04‐2012 NIL 96 120/80 N N N 21.4 0.9 16.1 6200 70/26/4 1.01 65 40 1 134 4.5 0.8
9 Mani  44yrs M 58722 20‐04‐2012 NIL 80 130/80 N N N 21.8 0.8 12.9 4800 60/39/1 4 128 30 0.7 138 3.8 0.9
10 Sekar 45yrs M 58572 20‐04‐2012 NIL 88 120/80 N N N 19.6 0.83 14.2 4500 53/42/5 1.6 128 26 0.8 143 3.5 0.9
11 Karthick 41yrs M 58890 20‐04‐2012 NIL 90 100/70 N N N 23.4 1.1 15.2 7800 60/38/2 1.47 108 32 1 140 3.5 0.8
12 Natesan 45yrs M 58907 20‐04‐2012 NIL 86 110/80 N N N 23.2 0.91 13.4 4545 72/27/1 2.6 72 20 0.7 120 4 1
13 Thambiah 45yrs M 69860 27‐04‐2012 NIL 82 100/60 N N N 29.2 1.1 14.5 4500 53/42/5 1.4 128 22 0.8 135 3 1
14 Rajkumar 48yrs M 65985 27‐04‐2012 NIL 72 130/90 N N N 20.1 0.7 15.3 4700 76/22/2 1.38 127 28 0.9 138 3.5 0.8
15 Manikumar 52yrs M 68157 27‐04‐2012 NIL 88 90/60 N N N 28.6 1.02 13.6 7700 71/26/3 2.2 32 26 0.9 138 3.5 0.9
16 Damodharan 55yrs M 69980 27‐04‐2012 NIL 82 130/90 N N N 31.2 1.2 12.4 4700 68/30/2 2.8 90 28 1 143 4.3 0.7
17 Prathab 46yrs M 69866 04‐05‐2012 NIL 88 120/80 N N N 20.4 0.9 12.8 6700 75/23/2 3.2 128 44 1.2 146 3.5 1
18 Sundaram 48yrs M 71228 04‐05‐2012 NIL 72 110/70 N N N 22.4 0.91 14.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8
19 Gyansingh 50yrs M 74880 04‐05‐2012 NIL 78 90/60 N N N 21.6 0.8 12.2 4395 67/31/2 1.5 100 44 1.2 145 3.9 0.8
20 Murali 53yrs M 70652 04‐05‐2012 NIL 80 120/80 N N N 29.4 1.2 12.4 4390 56/40/4 1.2 109 38 0.7 138 4 0.8
21 Gandhi 50yrs M 76023 11‐05‐2012 NIL 88 100/70 N N N 20.4 0.81 15.3 6570 49/48/3 1.7 120 42 1.1 140 3.6 0.9
22 Yusuf 55yrs M 71252 11‐05‐2012 NIL 84 100/60 N N N 29.4 1.02 16 7600 60/38/2 1.48 110 32 1 144 3.7 0.9
23 Veeraraghavan 50yrs M 76145 11‐05‐2012 NIL 90 110/80 N N N 19.7 0.78 15.2 7500 68/31/1 3.2 122 32 1.1 140 4.7 1.2
24 Kumaresan 54yrs M 72912 11‐05‐2012 NIL 78 140/70 N N N 26.2 0.92 13.4 7200 65/35/0 1.46 120 44 1.2 138 3.6 0.9
25 Surendar 51yrs M 74510 18‐05‐2012 NIL 80 110/80 N N N 25.4 1.1 13 9600 75/24/1 1.32 94 30 1 135 3.5 1.2
26 Murugasen 54yrs M 71228 18‐05‐2012 NIL 72 110/70 N N N 22.1 0.74 15.2 9000 74/23/3 1.01 124 39 1.4 130 3 0.8
27 Velu 55yrs M 79372 18‐05‐2012 NIL 86 110/70 N N N 25.6 1.14 14.3 7800 60/38/2 1.48 112 35 1.2 137 3.5 0.8
28 Gothandam 48yrs M 77591 18‐05‐2012 NIL 88 120/80 N N N 21.6 0.82 11.2 6550 49/48/3 1.8 119 43 0.9 147 3.8 0.8
29 Rajini 47yrs M 77586 25‐05‐2012 NIL 92 90/60 N N N 20.6 0.78 15.3 9300 74/23/3 3.3 124 40 1.2 134 3.6 0.9
30 Murugan 50yrs M 79453 25‐05‐2012 NIL 84 130/80 N N N 18.6 0.7 13.8 7900 68/29/3 3.2 121 27 1 140 4.2 0.6
31 Munnusamy 55yrs M 79467 25‐05‐2012 NIL 86 140/90 N N N 27.2 1.1 15.2 7600 60/38/2 1.48 107 31 1.2 135 3.8 1
32 Murali 48yrs M 78570 25‐05‐2012 NIL 86 130/80 N N N 19.4 0.72 13.5 7800 74/24/1 2.5 90 38 1 135 4 0.9
33 Karunakaran 50yrs M 77591 08‐06‐2012 NIL 88 120/80 N N N 23.5 0.92 14.2 6550 49/48/3 1.8 119 43 0.9 147 3.8 0.8
34 Mohan 48yrs M 79467 08‐06‐2012 NIL 86 140/90 N N N 23.5 0.96 16 7600 60/38/2 1.48 107 31 1.2 135 3.8 1
35 Munnusamy 48yrs M 78570 08‐06‐2012 NIL 86 130/80 N N N 24.8 0.94 15.7 7800 74/24/1 2.5 90 38 1 135 4 0.9
36 Ramu 55yrs M 83467 08‐06‐2012 NIL 90 120/60 N N N 26.6 0.98 15.2 8600 75/23/2 3.6 105 34 1 140 4.5 1
37 Rajendran 50yrs M 79989 15‐06‐2012 NIL 78 140/70 N N N 24.6 0.94 14.2 5600 65/34/1 1.48 120 44 1.2 132 4 1
38 Chandran 53yrs M 81556 15‐06‐2012 NIL 88 130/80 N N N 20.2 0.84 13.8 8100 68/29/3 3.5 111 38 0.7 145 3.8 0.7
39 Ponnusamy 55yrs M 87665 15‐06‐2012 NIL 84 110/70 N N N 23.4 0.92 12.8 7600 60/38/2 1.6 103 32 1 141 4.2 1
40 Mariappan 45yrs M 89854 15‐06‐2012 NIL 100 120/80 N N N 25.2 1.1 14.3 6970 49/48/3 1.8 90 40 1 145 3.8 0.8
41 Jeyakumar 46yrs M 89732 22‐06‐2012 NIL 72 110/70 N N N 26.4 1.12 12.5 6230 55/47/3 1.45 125 26 0.7 137 3.1 0.6
42 Sivaguru 50yrs M 79989 22‐06‐2012 NIL 78 140/70 N N N 29.2 1.2 14.2 5600 65/34/1 1.48 120 44 1.2 132 4 1
43 Seenivasan 50yrs M 71228 22‐06‐2012 NIL 72 110/70 N N N 30.4 1.18 12.5 9000 74/23/3 1.01 124 39 1.4 130 3 0.8
44 Devarajan 48yrs M 74510 22‐06‐2012 NIL 80 110/80 N N N 25.6 1.02 13 9600 75/24/1 1.32 94 30 1 135 3.5 1.2
45 Shanmugam 51yrs M 87665 29‐06‐2012 NIL 84 110/70 N N N 23.6 0.91 15.2 7600 60/38/2 1.6 103 32 1 141 4.2 1
46 Muthukumar 48yrs M 78570 29‐06‐2012 NIL 86 130/80 N N N 27.8 1.1 16.3 7800 74/24/1 2.5 90 38 1 135 4 0.9
47 Vasu 48yrs M 95366 29‐06‐2012 NIL 80 120/80 N N N 28.2 1.26 12.8 6110 66/32/2 2.5 110 39 1.1 130 4.2 1
48 Prabhu 42yrs M 96008 29‐06‐2012 NIL 88 110/70 N N N 24.1 0.9 13 7500 68/30/2 2.4 109 31 0.7 137 3.6 0.7
49 Dhanraj 55yrs M 94556 06‐07‐2012 NIL 92 120/80 N N N 19.2 0.8 14.3 7800 75/24/1 3 124 28 0.6 138 4.2 0.9
50 Vasu 50yrs M 71228 06‐07‐2012 NIL 64 110/70 N N N 28.6 1.14 16.2 9000 74/23/3 2.1 124 39 1.4 130 3 0.8
51 Soori 55yrs M 74510 06‐07‐2012 NIL 86 110/80 N N N 20.4 0.82 13 9600 75/24/1 2.35 94 30 1 135 4.2 1.2
52 Radhakrishnan 53yrs M 94578 06‐07‐2012 NIL 74 110/70 N N N 19.6 0.76 13.2 7600 70/27/3 3.2 95 38 0.9 140 3.8 0.9
53 Manikkam 55yrs M 69869 13‐07‐2012 NIL 88 110/70 N N N 20.4 0.82 12.5 6230 65/37/3 2.45 125 26 0.7 137 3.1 0.6
54 Parthasaarathy 54yrs M 73228 14‐07‐2012 NIL 92 100/60 N N N 20.2 0.82 13.2 7560 72/27/2 2.2 102 40 1 135 4 1.2
55 Anbu 50yrs M 74882 15‐07‐2012 NIL 80 120/70 N N N 27.2 1.02 14.1 8550 69/29/2 2.7 98 27 1.2 140 3 1
56 Mahesh 51yrs M 70662 16‐07‐2012 NIL 92 120/80 N N N 21.2 0.9 15.2 7300 65/32/3 2.48 102 31 0.7 132 3.5 0.9
57 Paramasivam 48yrs M 76025 17‐07‐2012 NIL 70 100/70 N N N 29.1 1.24 15.5 7690 62/36/2 3.2 96 38 1 145 4.3 1
58 Ponnusamy 50yrs M 72252 18‐07‐2012 NIL 72 110/60 N N N 28.4 1.1 13.6 7580 71/28/1 2.4 114 43 1 141 3.5 0.7
59 Shankar 50yrs M 76147 19‐07‐2012 NIL 86 110/80 N N N 26.8 0.98 11.3 7856 76/24/0 2.32 106 31 0.7 145 3 0.9
60 Aadi 52yrs M 72913 20‐07‐2012 NIL 76 100/60 N N N 21.5 0.82 14 8550 72/26/2 2.1 90 38 1.2 137 3.9 0.8
61 Nambi 48yrs M 74520 21‐07‐2012 NIL 84 110/80 N N N 30.2 1.2 15.2 6655 73/26/1 2.48 120 34 1.4 132 4 1.2
62 Murugan 55yrs M 71228 22‐07‐2012 NIL 90 110/70 N N N 20.5 0.86 16.2 7900 60/38/2 2.8 116 44 1 130 3.6 0.9
MASTER CHART NON DIABETICS
CBC RFT
63 Ramachandran 50yrs M 79378 23‐07‐2012 NIL 86 110/70 N N N 28.8 0.96 14.6 8646 55/42/3 3.3 95 38 1 135 3.7 0.6
64 Chandru 47yrs M 77590 24‐07‐2012 NIL 78 120/80 N N N 24.2 0.86 15.2 9600 60/37/1 3.2 106 32 1 141 4.7 1
65 Veerasamy 55yrs M 77486 25‐07‐2012 NIL 72 90/60 N N N 22.6 0.84 14.1 6100 74/24/2 2.48 100 40 1.1 135 3.6 0.9
66 Raja 65yrs M 79454 26‐07‐2012 NIL 80 130/80 N N N 26.6 0.92 14.3 7560 53/45/3 2.5 118 26 0.7 130 3.5 1
67 Manikam 60yrs M 79468 27‐07‐2012 NIL 84 140/90 N N N 26.4 0.84 13.2 6876 76/23/1 3.8 96 44 0.6 137 3 1
68 Mannar 58yrs M 78571 28‐07‐2012 NIL 86 130/80 N N N 23.2 0.84 16 6200 72/25/3 2.48 104 39 1.4 138 3.5 0.7
69 Ramasamy 62yrs M 77571 29‐07‐2012 NIL 80 120/80 N N N 20.2 0.84 15.8 7600 68/31/1 2.5 122 30 1 130 4 1
70 Kumar 65yrs M 79469 30‐07‐2012 NIL 88 140/90 N N N 27.2 0.94 13.6 8000 75/23/2 3.6 96 32 0.9 135 3.6 0.8
71 Gajendran 58yrs M 78575 31‐07‐2012 NIL 92 130/80 N N N 22.1 0.82 12.5 8600 75/24/1 2.48 92 40 0.7 140 3.7 0.6
72 Saminathan 60yrs M 83477 01‐08‐2012 NIL 72 120/60 N N N 28.6 0.98 15.6 9684 67/30/3 3.5 104 27 1 137 4.7 1
73 Kuppusamy 58yrs M 79990 02‐08‐2012 NIL 68 140/70 N N N 25.2 0.96 14.9 8800 58/41/1 2.6 99 31 1.2 135 3.6 0.8
74 Kamalakanan 62yrs M 78450 03‐08‐2012 NIL 76 130/80 N N N 22.6 0.86 16.2 8110 53/45/2 2.6 122 38 0.7 140 3.5 1.2
75 Praveen 65yrs M 78956 04‐08‐2012 NIL 92 110/70 N N N 25.1 0.9 14.9 8500 60/39/1 2.45 106 43 1 132 3 1
76 Rathinam 60yrs M 77456 05‐08‐2012 NIL 84 120/80 N N N 27.2 0.96 14 9200 68/32/0 2.48 98 31 1 145 3.5 0.9
77 Swami 62yrs M 89585 06‐08‐2012 NIL 90 110/70 N N N 29.1 1.1 15.4 6550 65/34/1 2.1 88 38 0.7 141 4 1
78 Rajan 65yrs M 89562 07‐08‐2012 NIL 88 120/80 N N N 23.1 0.86 13.2 9500 75/23/2 2.32 100 34 1.2 145 4.5 0.7
79 Karupaiya 58yrs M 78563 08‐08‐2012 NIL 72 110/70 N N N 24.6 0.89 15.4 6850 74/25/1 2.6 120 44 1.4 137 4 0.8
80 Raja 62yrs M 98563 09‐08‐2012 NIL 84 130/80 N N N 28.2 0.94 15.8 7500 61/38/1 2.5 96 38 1 132 3.8 1.2
81 Murugaiyan 58yrs M 78456 10‐08‐2012 NIL 76 120/70 N N N 29.4 1.1 14.2 4500 51/46/3 2.5 98 32 1 130 4.2 0.9
82 Nataraj 65yrs M 89745 11‐08‐2012 NIL 86 120/80 N N N 22.8 0.85 12.8 6750 74/22/4 2.3 104 40 1 135 3.8 0.6
83 Ravi 60yrs M 68458 12‐08‐2012 NIL 74 120/80 N N N 22.2 0.8 13.6 8900 75/23/2 3 118 26 1.1 141 3.1 1
84 Mahendran 61yrs M 78498 13‐08‐2012 NIL 78 90/60 N N N 21.6 0.82 15 5200 74/23/3 2.01 94 44 0.7 135 4 0.9
85 Ramkumar 65yrs M 65265 14‐08‐2012 NIL 72 120/80 N N N 20.6 0.7 16.4 5800 67/31/2 2.32 106 39 0.6 130 3 1
86 Kadhir 62yrs M 73652 15‐08‐2012 NIL 80 130/80 N N N 26.2 0.98 14.5 5500 56/40/4 3.2 100 30 1.4 137 4.2 1
87 Palani 64yrs M 74326 16‐08‐2012 NIL 84 120/80 N N N 24.2 0.94 14.6 7500 50/48/2 1.45 120 32 1 138 3.8 0.7
88 Babu 56yrs M 98231 17‐08‐2012 NIL 86 100/70 N N N 24.6 0.86 16 5000 60/38/2 1.5 115 34 0.9 130 3.1 0.8
89 Saravanan 60yrs M 98845 18‐08‐2012 NIL 80 110/80 N N N 19.4 0.78 15.4 5500 68/31/1 2.3 112 44 0.7 135 4 0.6
90 Durai 58yrs M 81258 19‐08‐2012 NIL 88 100/60 N N N 30.6 1.15 14.6 5700 65/35/0 2.5 100 38 1 140 3 1
91 Kannan 68yrs M 86523 20‐08‐2012 NIL 92 130/90 N N N 20.1 0.84 13.5 7800 75/24/1 2.5 96 32 1 137 3.8 0.8
92 Selvam 70yrs M 89897 21‐08‐2012 NIL 66 120/90 N N N 26.1 0.96 16.4 8700 74/23/3 2 104 40 1.1 135 4.2 1.2
93 Vignesh 70yrs M 85276 22‐08‐2012 NIL 86 130/90 N N N 22.6 0.92 15.4 6750 60/38/2 3 120 26 0.7 130 3.8 1
94 Aravind 72yrs M 77498 23‐08‐2012 NIL 88 130/80 N N N 20.5 0.86 13.2 9850 49/48/3 2.36 122 44 0.6 137 3.1 0.9
95 Balasekar 68yrs M 69565 24‐08‐2012 NIL 80 120/90 N N N 22.4 0.82 14.2 4500 74/23/3 2.32 108 39 1.4 138 4 1
96 Kesavan 66yrs M 89137 25‐08‐2012 NIL 86 110/70 N N N 20.2 0.78 16.2 4300 68/29/3 3.2 96 30 1 130 3 0.7
97 Perumal 68yrs M 79135 26‐08‐2012 NIL 72 120/80 N N N 26.5 0.94 13 6500 49/48/3 2.4 100 32 0.9 135 3.8 0.8
98 Prasanth 70yrs M 84625 27‐08‐2012 NIL 76 130/90 N N N 20.2 0.84 14.6 7400 74/23/3 3.2 114 30 1 140 4.2 0.9
99 Varatharajan 72yrs M 96325 28‐08‐2012 NIL 90 120/90 N N N 22.5 0.92 16.4 8500 68/29/3 2.45 120 32 0.9 137 3.8 1
100 Sridhar 70yrs M 74125 29‐08‐2012 NIL 86 110/70 N N N 19.6 0.82 17.4 7530 69/28/3 2.56 118 34 0.8 136 3.9 0.8
HIV OT CHOLESTROL(mg/d
Serum Total 
TESTOSTERONE 
(ng/dl)
DB (mg/dl) OT (IU/L) PT  (IU/L) TP (g/dl)
0.3 28 20 6.5 negative 182 820
0.3 20 32 6.2 negative 184 614
0.4 25 38 6.4 negative 176 812
0.2 28 20 5.4 negative 190 616
0.4 25 39 7 negative 230 450
0.4 21 22 5.8 negative 186 712
0.2 24 36 6.2 negative 180 720
0.2 29 31 5.8 negative 190 720
0.3 24 28 6.2 negative 186 840
0.4 28 36 6.2 negative 184 820
0.3 28 32 7 negative 200 740
0.4 24 36 6.9 negative 198 550
0.4 24 29 6.2 negative 220 470
0.2 27 32 5.8 negative 184 680
0.2 28 32 6.4 negative 216 720
0.2 23 30 6.8 negative 236 813
0.4 28 32 7 negative 186 720
0.3 23 20 7 negative 180 720
0.2 32 20 6.7 negative 188 728
0.2 31 21 7 negative 226 440
0.2 25 38 6.2 negative 184 685
0.2 28 32 6.8 negative 210 520
0.3 27 22 6.6 negative 186 572
0.3 28 16 6.4 negative 206 510
0.3 27 22 7 negative 200 620
0.3 23 23 7 negative 188 710
0.2 32 20 6.8 negative 206 670
0.2 28 30 6.2 negative 190 770
0.3 29 34 6.6 negative 186 620
0.1 20 32 6.1 negative 186 720
0.3 28 36 6.2 negative 200 690
0.3 30 28 7 negative 178 612
0.2 28 30 6.2 negative 186 640
0.3 28 36 6.2 negative 180 714
0.3 30 28 7 negative 182 780
0.2 24 36 6 negative 194 609
0.3 28 30 6.5 negative 198 780
0.2 24 28 5.8 negative 196 790
0.3 28 30 6.5 negative 192 610
0.2 26 30 7.2 negative 200 550
0.1 28 16 6.2 negative 196 606
0.3 28 30 6.5 negative 216 590
0.3 23 25 7 negative 230 520
0.3 27 18 7 negative 190 510
0.3 28 30 6.5 negative 192 580
0.3 30 28 7 negative 196 620
0.3 22 35 6.8 negative 220 701
0.2 22 27 6.2 negative 210 554
0.2 28 36 6.5 negative 180 720
0.3 23 20 7 negative 200 750
0.3 27 22 7 negative 186 660
0.2 21 27 6.6 negative 180 624
0.1 28 16 6.2 negative 188 740
0.2 30 20 6.8 negative 184 640
0.3 30 32 6.2 negative 210 560
0.2 16 38 6.6 negative 180 614
0.3 30 20 6.1 negative 232 468
0.2 24 39 6.2 negative 200 565
0.1 42 22 7 negative 196 580
0.3 30 36 6.2 negative 184 620
0.3 28 31 6.2 negative 230 562
0.3 35 28 7 negative 184 670
LFT
0.3 27 32 6 negative 224 420
0.3 36 36 6.5 negative 196 620
0.3 20 28 5.8 negative 188 640
0.2 22 30 6.5 negative 210 482
0.2 27 36 7.2 negative 200 620
0.3 16 28 6.2 negative 184 562
0.3 30 36 6.5 negative 180 710
0.2 16 30 7 negative 230 487
0.3 30 28 7 negative 182 580
0.3 25 30 6.5 negative 210 670
0.3 18 30 7 negative 198 520
0.3 30 16 6.8 negative 188 560
0.2 28 30 5.8 negative 200 510
0.2 35 28 6.5 negative 206 540
0.3 27 28 7.2 negative 224 639
0.1 36 30 6.2 negative 198 580
0.3 20 24 6.5 negative 180 550
0.3 22 28 7 negative 212 480
0.2 27 24 6.5 negative 220 510
0.3 16 28 7 negative 186 610
0.3 23 26 6.8 negative 190 580
0.2 32 28 6.2 negative 184 610
0.3 28 28 6.8 negative 180 540
0.3 29 23 6.2 negative 200 510
0.3 20 23 6.6 negative 196 585
0.3 28 32 6.1 negative 189 582
0.2 30 28 6.2 negative 182 610
0.2 28 29 7.2 negative 236 720
0.3 28 20 6.2 negative 186 462
0.1 30 28 6.5 negative 204 302
0.3 24 30 7 negative 198 460
0.3 28 28 6.5 negative 190 570
0.2 24 23 7 negative 194 480
0.3 28 27 6.5 negative 180 528
0.3 29 28 7.2 negative 200 370
0.2 20 30 6.2 negative 192 598
0.3 28 23 6.5 negative 180 465
0.3 19 21 7.5 negative 186 475
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and its levels decreases with aging. Men with type 2 diabetes mellitus have low testosterone levels,
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